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ACHM Achromatopsia 
ANOVA  analysis of variance 
Bp  basepair 
Ca²+ Calcium  
cAMP cyclic adenosinemonophosphate 
Cap  Capsid 
cDNA complementary DNA 
cGKI cGMP dependent kinase type 1 
cGKII cGMP dependent kinase type 2 
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GCAP guanylyl cyclase activating protein 
GCL ganglion cell layer  
GCL ganglion cell layer 
GFAP glial fibrillary acidic protein 
GKAP cGMP-dependent kinase anchoring proteins 
GUCY guanylyl cyclase 
Glypho glycogen  
HEK cells human embryonic kidney cells 
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hmc hydroxy-methy-cytonsine  
ILM inner limiting membrane  
INL inner nuclear layer 
IPL inner plexiform layer  
IPL inner plexiform layer 
IS inner segment 
ITRs  inverted terminal repeats 
kDa kilodalton 
KO knockout 
Na+ sodium  
OCT optical coherence tomography 
OD oculus dexter/right 
ON optic nerve 
ONL outer nuclear layer 
OLM outer limiting membrane 
OPL outer plexiform layer  
ORI  origin of replication 
OS oculus sinister/left 
OS outer segment 
PB phosphatpuffer 
PCR  polymerase chain reaction 
PDE phosphodiesterase 
PDE  phophodiesterase 
PFA  paraformaldehyd 
qPCR  quantitative polymerase chain reaction 
rAAV  recombinant adeno-associated virus 
Rep  replication 
RG red/green opsin  
Rho  rhodopsin 
RNA ribonucleotideacid 
RP Retinitis pigmentosa  
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RPE  retinal pigment epithelium 
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SDS sodium dodecylsulfate 
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cSLO confocal laser scanning ophthalmoscopy 
SV40 simian Virus 40 
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Figure 1.1: Anatomy of the human eye. The eye is 
protected from the outside by the sclera, in the choroid 
the blood vessels are located which supply blood to the 
retina. The inner layer of the eye is the light-sensitive 
retina with the fovea, responsible for sharp vision. 
 Introduction  
 Vision 
The light sensitive part of the eye is the retina, a thin three-dimensional network of neurons 
covering the back surface of the eye. The retina is considered as an outgrowth of the developing 
brain and can be seen as a part of the central nervous system (CNS). It is connected to the visual 
cortex via the optic nerve and the optic chiasm through the lateral geniculate nucleus. 
In mammals vision begins in the outer layer of the retina in so called photoreceptors. To reach 
them, light has to pass the cornea, the lens, the vitreous body (Figure 1.1) and all layers of the 
retina (Figure 1.2). Vision relies not only on proper functioning of photoreceptors itself, but also 
on a proper interconnection between all different types of neurons in the retina. The retina is 
structured in a three cell layer dimension. These layers are termed: the ganglion cell layer (GCL), 
the inner nuclear layer (INL) and the outer nuclear layer (ONL) (Figure 1.2). The GCL is 
composed of the cell bodies of ganglion and 
displaced amacrine cells, while in the INL the 
cell bodies of bipolar, horizontal, amacrine, as 
well as Müller glia cells are located. The ONL 
on the other hand is assembled by the cell 
bodies of the two types of photoreceptor: rods 
and cones (Figure 1.2). These three nuclear 
layers are separated by dense networks of 
neuronal synapses creating three further layers: 
the outer plexiform layer (OPL), the inner 
plexiform layer (IPL) and the nerve fibre layer 
(NFL) (Figure 1.2). In the OPL the 
projections of rods and cones synapse via rod 
spherules and cone pedicles to the dendrites of bipolar and horizontal cells. In the IPL axon 
terminals of bipolar cells and dendrites of ganglion and amacrine cells connect to each other. In 
the nerve fibre layer (NFL) the axonal fibres of ganglion cells merge in the optic nerve and 
connect the retina to the brain.  
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Temporal to the optic nerve the macula is located comprising the fovea centralis which encloses 
the highest density of cones. 10 % of the 4.5 million cones existing in the retina are situated in 
the fovea where no rods are present (Figure 1.1). This part is responsible for sharp central vision. 
Furthermore the vitreous body is separated from the retina by astrocytes and the end feet of 
Müllerth glia cells, forming the innermost layer, the inner limiting membrane (ILM) (Figure 
1.2). 
Figure 1.2: Retinal structure: Ten layers are incooperated in the highly complex structure of the retina. The 
retinal pigment epithelium (RPE) is responsible for nutrients supply for the retina, embedding the light-sensing 
rod and cone photoreceptors in the outermost layer of the retina. In the inner nuclear layer (INL) the 
connecting neurons: amacrine, bipolar and horizontal cell can be found. At the innermost layer the ganglion 
cells are located, which are directly connected to the brain through the optic nerve. 
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Figure 1.3: The phototransduction cascade: 
The bound chromophore of the opsin gets 
photoisomerized by light and activates the 
coupled G-protein transducin. The transducin 
α-subunit then activates the phosphodiesterase 
(PDE6), which degrades cGMP to GMP. Due 
to the drop of cGMP level, the cyclic 
nucleotide-gated (CNG) channels close, 
causing a shutdown of Ca2+ influx and a 
hyperpolarization of the outer segment 
membrane potential. Due to decrease of 
intracellular Ca2+ levels, Ca2+-free guanylate-
cyclase-activating protein (GCAP) stimulates 
the guanylate cyclase (GC) for increased 
synthesis of cGMP. As soon as the light 
stimulus stops, cGMP-levels are rapidly 
restored, since PDE is inactive. Additionally 
GCs are inactive again and CNG channels are 
opened causing a depolarization of the 
membrane. This is called dark current . 
At the bases of rods and cones there is the outer limiting membrane (OLM), separating the nuclei 
of photoreceptors from the outer segments (Figure 1.2). At last the outer segments in the 
photoreceptor layer are embedded in the outermost layer of the retina, the retinal pigment 
epithelium (RPE).  
 
Vision begins in the outer segments of the photoreceptors were light is transformed into an 
electrical signal. Located in the outer segments of photoreceptors light sensitive G-protein 
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coupled receptors, so called opsins, transform into a new conformation upon interaction with a 
photon and activate a downstream cascade resulting in signalling action potentials. This 
conformational change is triggered by the photoreactive part of the opsins the retinal 
chromophore. In the well-studied rod opsin called rhodopsin, the chromophore 11-cis-retinal 
isomerizes and transforms rhodopsin to metarhodopsin II and a release of all-trans-retinal. 
Caused by the conformational change the associated G-protein transducin gets activated. In cones 
one of the respective cone opsins (S-, M- or L-Opsin) undergoes a similar conformational change. 
The number of activated transducins is directly linked to the intensity of the light stimulus. Upon 
activation transducins in turn stimulate the 
phosphodiesterase 6 (PDE6), a cGMP hydrolysing 
enzyme, thus, leading to a drop of the intracellular level of 
this second messenger. 
The second messenger cGMP plays a central role in the 
visual cascade. It is a modulator of the cyclic nucleotide-
gated (CNG) channel, a nonselective cation channel, 
located in the plasma membrane of the photoreceptor 
outer segment. Upon binding, cGMP gates the CNG 
channel open, leading to a sodium (Na+) and calcium 
(Ca2+) ion influx. Upon light stimulation, the cGMP 
degrading PDE is activated leading to a fast decay of 
cGMP and closure of the CNG channels. The 
intracellular calcium concentrations declines and the 
photoreceptor cell hyperpolarises from -40 mV to -70 
mV. As a consequence presynaptic voltage-dependent 
calcium channels close and the synaptic glutamate-release is terminated (Arshavsky and Burns, 
2012, Luo et al., 2008). The guanylyl cyclase activating protein (GCAP) is regulated by calcium. 
It has two intracellular Ca2+ binding sites: if these binding sites are unoccupied, GCAP stimulates 
the cGMP-production by activation of guanylyl cyclase (Gucy) (Yang et al., 1999, Palczewski et 
al., 2004, Lowe et al., 1995, Laura and Hurley, 1998). 
Gucys can be membrane bound or soluble enzymes synthesizing cGMP from GTP. Membrane 
bound Gucys have an extracellular ligand binding domain, a short transmembrane region and an 
Figure 1.4: Structure of the 
membrane bound guanylyl 
cyclase (GC). GCs are anchored 
in the membrane. This 
transmembrane region combines 
an extracellular region, which can 
be bound by ligands and the 
intracellular domain. This domain 
has a protein-kinase like, hinge 
and catalytic region (Kuhn, 2003). 
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intracellular catalytic domain (Figure 1.4). The activity of the membrane bound Gucys present in 
photoreceptors is not dependent on gaseous molecules (NO/CO2) like soluble Gucys but rather 
on small proteins. Gucy-E which is expressed in rod and cones and Gucy-F, only present in rods, 
are both activated by small retinal-specific molecules, the guanylyl-cyclase-activating-proteins 
(GCAP) 1, 2 and 3 (Kuhn, 2003). 
The activity of Gucys is crucial for a fast recovery of the dark current. During a light stimulus 
PDE hydrolyses the newly synthesized cGMP but as soon as the light stimulus ends PDEs are 
inactivated and cGMP levels increase  - thereby gating the CNG-channel causing an influx of 
Ca²+ and Na+. This fast reaction causes a depolarisation of the outer segments plasma membrane 
(-40mV), which in turn activates presynaptic voltage-dependent calcium channels and triggers 
transmitter release at the synapse. GCAP now binds calcium and guanylyl cyclase is inhibited 
(Kuhn, 2003). Hence further cGMP production is interrupted and the cGMP level remains 
stable until a new light stimulus follows.  
 
 Achromatopsia 
Genetic disruption of proteins involved in the photo-transduction cascade are known to lead to 
photoreceptor degeneration (Biel and Michalakis, 2007, Boye et al., 2013, Roosing et al., 2014, 
Schon et al., 2013, Wright et al., 2010) Several retinal diseases have already been associated to a 
genetic cause. Non- and missense mutations have been identified in human patients suffering 
from retinal dystrophy affecting either rods or cones. The most common form of inherited retinal 
degenerative disease is Retinitis Pigmentosa (RP), causing a degeneration of rod photoreceptors 
while secondary a loss of cones is observed (Hartong et al., 2006). Achromatopsia (ACHM) is a 
retinal degenerative disorder affecting cone photoreceptors. ACHM shows an autosomal-recessive 
inheritance and has a prevalence of roughly 1 of 30 ,000 worldwide (Sundin et al., 2000, 
Pokorny et al., 1982). 
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As for all other inherited degenerative retinal diseases, there is currently no treatment available. 
Currently, there are six known ACHM causing genes CNGA3, CNGB3, GNAT2, PDE6C, 
PDE6H and ATF6. Most of them encode important proteins involved in the cone photo 
transduction cascade like CNGA3, CNGB3, GNAT2, PDE6C and PDE6H (Trifunovic et al., 
2010). The most recent addition to the ACHM gene list, is ATF6 encoding for a protein 
involved in the unfolded protein response (UPR) process (Kohl et al., 2015). The UPR process 
fixes misshaped or falsely folded proteins. If these proteins are not fixed by the UPR process they 
not only do not work properly but furthermore might accumulate in the cell and cause cell stress 
(Kohl et al., 2015).  
Patients suffering from ACHM are lacking cone photoreceptor function by birth thus, struggling 
with strongly compromised daylight vision (Figure 1.5). In addition to their inability to 
distinguish between colours, patients suffer from very low visual acuity, pendular nystagmus and 
eccentric fixation (Figure 1.5). Moreover, their cone photoreceptors degenerate over time. The 
subsequent loss of cones causes a sustained activation of rods and as a consequence patients 
experience an increased sensitivity to light, termed photophobia  (Pokorny et al., 1982, Kohl et 
al., 1998, Eksandh et al., 2002). 
Diseased patients show only residual or absent cone function in full-field electroretinography 
(ERG) measurements (Kohl et al., 2000). Monitoring the morphology of diseased retina by 
spectral domain optical coherence tomography (OCT) a loss of inner and outer segments of 
cones can be seen at earlier stages (Figure 1.6 B), while a complete loss of cones in the 
photoreceptor layer (Figure 1.6 C) and an atrophy of retinal pigment epithelium (RPE) is 
Figure 1.5: Vision of an Achromatopsia patient (B) compared to a healthy individual (A) . Achromatopsia 
is a disease causing degeneration of photoreceptors in the retina. As a result of this degeneration, patients lack 
colour-vision. They furthermore suffer from light-sensitivity and blurry vision. 
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apparent at later stages of the disease (Figure 1.6 D) (Genead et al., 2011, Thiadens et al., 
2010b).  
A disruption in the CNGB3 locus is the most common affected locus in the Western world with a 
prevalence of approximately 50 % (Kohl et al., 2005). Roughly 25-30 % of ACHM patients carry 
a genetic disruption in the locus of the CNGA3 subunit, involving over 100 different mutations 
(Thiadens et al., 2010a, Ma et al., 2013). Less than 2 % of ACHM patients carry a GNAT2, 
Figure 1.6: Fundus and Optical coherence tomography (OCT) images of Achromatopsia patients at different 
stages of the disease (A) Normal OCT and fundus images of a nine--year-old patient with a CNGA3 mutation. (B) 
The OCT image of an eight-year-old Achromatopsia patient carrying CNGB3 mutations displays the absences of 
inner and outer segments of cones while the fundus still shows a normal appearance of the macular. (C) In a 15-year 
old patient with CNGB3 mutations, bubbles in the fovea of the OCT image show a complete loss of cones. The 
fundus image shows no abnormal morphology (D) Images of a patient also carrying CNGB3 mutations in a later stage 
show a complete loss of cones and macular retinal pigment epithelium (RPE) atrophy. Images adapted from (adapted 
from Thiadens et al., 2010b) 
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PDE6C or PDE6H mutation (Schon et al., 2013), only very few cases of an ATF6-mutation are 
known (Kohl et al., 2015). Other mutations still remain unknown. 
CNG channels are heterotetrameric non-selective cation channels expressed in the outer segments 
of photoreceptors. The composition of the four subunits is tissue-specific and each subunit is 
formed by six transmembrane domains (TMD 1-6, Figure 1.6) (Yu et al., 2005). The cone 
specific CNG channel consists of three CNGA3 and one CNGB3 subunits and is modulated by 
cGMP (Figure 1.6) (Peng et al., 2004, Shuart et al., 2011). 
 
 The role of cGMP in photoreceptor degeneration 
In 1974 already Farber and Lolley suggested that cGMP is an essential factor in the degeneration 
of photoreceptors (Farber and Lolley, 1974). In their study they were able to show an 
accumulation of this second messenger in cyclic nucleotide phosphodiesterase activity deficiency 
and assumed that this accumulation might result in an imbalance of the photoreceptor 
metabolism. More recent studies show an accumulation of cGMP in photoreceptors of mice 
suffering from different kinds of retinal degeneration (Xu et al., 2013, Paquet-Durand et al., 
2009, Michalakis et al., 2010, Bowes et al., 1990). Although this phenomenon has been 
described for the first time almost four decades ago it is still not known whether cGMP directly 
contributes to the degeneration process of photoreceptors. 
Figure 1.6: Cyclic nucleotide-gated (CNG) channel. 
CNG channels are heterotetrameric cation channels. In the retina 
they are located in the outer segments of photoreceptors (A). The 
cone-specific CNG-channel is formed by three CNGA3 und one 
CNGB3 subunit (B). Each of these subunits is composed of 6 
transmembrane domains (1-6), C = Carboxy terminus, CNBD = 
cyclic nucleotide-binding domain; N = amino-terminus (C). 
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In mammals cGMP is involved in various physiological functions ranging from contractility of 
cardiac and smooth muscles, cellular growth, neuronal excitability and neuronal plasticity, 
immune response and inflammation, as well as sensory transduction (Feil et al., 2005, Kemp-
Harper and Feil, 2008). In the retina cGMP is the central second messenger of the 
phototransduction cascade. Disruption in the decay of this essential molecule is known to lead to 
photoreceptor dysfunction. Mutations in the PDE6b gene have been detected in autosomal 
recessive RP patients (McLaughlin et al., 1993). Moreover inbred laboratory mice strains termed 
rd1
nonsense mutation in the Pde6b locus (Drager and Hubel, 1978, Pittler and Baehr, 1991). 
Interference with the production of cGMP by knocking out the guanylyl cyclase was also shown 
to lead to dysfunction and changes in the viability of cones while rods showed no change in 
morphology up to one year after birth (Yang et al., 1999). Interference with the transcription of 
GTP 
cGMP 
Phospho-
diesterases 
Cyclic 
nucleotide 
gated channel 
PDE 
soluble  
guanylyl cyclase 
membrane bound  
guanylyl cyclase 
cGMP-dependent 
kinases 
substrates 
Figure 1.7: cGMP signalling pathway. cGMP is synthesized from GTP by the guanylyl cyclase (Gucy). 
Gucys can be either soluble or membrane-bound. The major difference between these two types is that the 
soluble GC gets activated by NO and the membrane-bound GC has an external ligand binding domain. 
Known targets of cGMP are cyclic-nucleotide-gated (CNG) channels, phosphodiesterases (PDEs) and cGMP 
dependent kinases (cGKs) which in turn phosphorylate protein substrates. Not all cGK-substrates are identified 
yet. Especially substrates in the CNS and the retina remain to be elucidated. 
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the guanylyl cyclase activating protein (GCAP) has yet been shown to result in progressive cone-
loss in mice (Payne et al., 1998). These studies further support the theory that malfunction of the 
vision cascade results in cell death in photoreceptors. However the question remains whether 
cGMP-levels influence the viability of cones. 
The main cGMP effectors in the retina are the CNG channel and the phosphodiesterases (Figure 
1.7) (Zhang and Cote, 2005). In addition, the cGMP dependent kinases (cGK) are also expressed 
in photoreceptors, but their function in this cell type is not understood (Figure 1.7) (Zhang and 
Cote, 2005). The cGKs are serine/threonine kinases phosphorylating the amino acids (AA) serine 
and threonine of their protein targets in the context of the general -R/K(2-3)-X-S/T-X motif 
{Kennelly, 1991 #295}. In mammals two genes are known: Prkg1 coding for the cGK type 1 
(cGKI) and Prkg2 encoding the membrane bound kinase cGK type 2 (cGKII). In Prkg1, 
alternative splicing of exons encoding the N-terminus results in two different isoforms 
(cGKI alpha 671 AA, 76 kDa and cGKI beta 686 AA, 78 kDa) with distinct functions and 
cellular distribution (Hofmann and Wegener, 2013, Ruth et al., 1997). Both cGKI isoforms are 
located in the cellular cytoplasm (Wernet et al., 1989), while the N-terminus of cGKII is 
anchored in the cell membrane (Vaandrager et al., 1996, Jarchau et al., 1994). All cGKs share a 
similar structure (Figure 1.8). They are homodimers consisting of three functional domains: the 
N-terminus, the regulatory domain and the catalytic domain (Hofmann et al., 2006, Gamm et 
al., 1995). The N-terminal domain is essential for dimerization, inhibition of the kinase activity 
Figure 1.8: Structure of the cGMP-depenednt kinases (cGKs). Structurally cGKs have a very similar composition: 
They have a N-terminus responsible for the dimerization, inhibition and substrate-specificity, a regulatory domain 
made out of two cGMP-binding domains and a catalytic domain with an ATP- and a substrate-binding pocket. The 
major difference between the kinases can be detected in the variable N-terminus. 
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and substrate specific targeting (Gamm et al., 1995, Kim et al., 2011, Landgraf et al., 1990). It 
contains the major structural difference between the kinases. Its leucine zipper, a protein-protein 
interaction domain, can dimerize the homomers and bind cGMP-dependent kinase anchoring 
proteins (GKAPs) (Casteel et al., 2010). The auto-inhibitory domain which is located between 
the leucine zipper and the regulatory domain prevents the activity of the phosphotransferase in 
absence of cGMP. Furthermore, the N-terminus targets the kinase to different subcellular 
localisations and comprises several auto-phosphorylating-sites. Upon cGMP-binding 
Thr59/Ser64 and Ser80 are auto-phosphorylated and increase the spontaneous activity of cGK 
and enhances its activity upon phosphorylation (Ruth et al., 1997).  
At the regulatory domain two cGMP binding pockets are located. One of these domains has a 
high affinity for cGMP and the other shows a markedly lower affinity. As soon as both binding 
pockets are bound by cGMP the kinase undergoes a conformational change revealing the catalytic 
domain for substrate-binding (Figure 1.9) (Kim et al., 2011, Landgraf et al., 1990, Ruth et al., 
1997). The C-terminal catalytic domain 
region for MgATP and for the substrate. Upon binding, ATP and the substrate are in close 
proximity and a phosphate group can be transferred by the catalytic domain to a serine or 
threonine (Figure 1.9) (Pfeifer et al., 1999, Hofmann, 2005). 
 
Figure 1.9: 
Conformational change of 
the cGMP-dependent 
kinases upon cGMP 
binding. At the regulatory 
domain two cGMP binding 
pockets are located. One of 
these sequences has highly 
affinity for cGMP and the 
other markedly lower 
affinity. Only if both 
sequences are occupied the 
secondary structure 
undergoes a conformational 
change unveiling the 
catalytic domain for 
substrate-binding. 
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After truncation of the N-terminal regulatory domain of cGKI, the kinase is no longer subject to 
auto-inhibitory domain-mediated repression and can continuously phosphorylate proteins, the 
kinase is then constitutive active (Ruth et al., 1997, Boerth and Lincoln, 1994, Deguchi et al., 
2004). Most of these previous structural investigations have solely focused on the cGKI. Due to 
the high sequence homology it can be assumed that the structural composition of cGKII would 
be very similar.  
For the functional analysis of the cGKs, knock out mouse lines have been generated. cGKI 
knock-out mice have a severely decreased life expectancy and die about six weeks after birth due 
to acute problems in the smooth muscle formation (Wegener et al., 2002). This short life 
expectancy makes long-term studies impossible. Thus cGKI KO mice were generated carrying a 
rescue knock in the smooth muscle cells (Weber et al., 2007). Caused by the knock-in both 
isoforms are expressed in the smooth muscle cells and the mice have a significantly higher life 
expectancy (Weber et al., 2007). cGKII knockout mice on the other hand exhibit less severe 
pathological effects upon the phenotype (Pfeifer et al., 1996). They have a normal life expectancy, 
are resistant against enterotoxin STa but are in general 30 % smaller compared to their littermates 
caused by a deficit in the skeleton growth (Pfeifer et al., 1996). 
 
 Animal models to study retinal degeneration  
Animal models are vital for ophthalmologic research and have already helped improving our 
understanding about retinal diseases. They are indispensable means to unravel genetic and 
biochemical mechanisms in the retina, especially, since currently in vitro retinal cell and tissue 
culture models cannot sufficiently mimic the highly complex in vivo situation. 
As previously mentioned, there are naturally occurring mouse models carrying a mutation leading 
to retinal degeneration like for example the rd1 mouse discovered in 1976 leading to rod 
degeneration (Drager and Hubel, 1978, Pittler and Baehr, 1991) and the Gnat2 mouse model 
which resembles the Achromatopsia phenotype (Jobling et al., 2013). Over the past forty years 
several dog breeds have been diagnosed to suffer from retinal degeneration like the Labrador 
retriever (Kommonen et al., 1994), the Swedish briard (Narfstrom et al., 1989, Wrigstad et al., 
1994, Veske et al., 1999) or the Irish setter (Aquirre et al., 1978, Farber and Lolley, 1974, Suber 
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et al., 1993). In the Alaskan malamute and the German shorthaired pointer deletion and missense 
mutations in the Cngb3 locus could be detected. These dogs also show characteristics similar to 
ACHM patients (Komaromy et al., 2010, Sidjanin et al., 2002) Furthermore an Israeli sheep 
breed was recently found to carry a premature stop codon in the Cnga3 subunit which also has 
been shown to lead to ACHM (Shamir et al., 2010, Reicher et al., 2010).  
Larger animals are very useful tools for clinical trial-enabling translational studies focusing on 
efficacy and safety of treatments. Eyes of dogs or pigs are anatomically more similar to the human 
eye and harbour a greater proportion of cones than the rodent retina (Li et al., 1998b, Petters et 
al., 1997). In addition the larger size makes surgical procedures and follow-up examinations easier 
and more precise. The canine retina contains an area 
macula, enriched with cones, making the canine eye favourable compared to other species 
(Mowat et al., 2008). 
Mice on the other hand have always been a popular option for animal experiments. Considering 
their short gestation time they do not only provide more offspring but also allow fast cross-
breeding possibilities with other mouse lines. Due to the accelerated life span of these animals it is 
possible to examine diseases at late stages and to examine long-term effects in a short timeframe. 
The biggest advantages are probably that a vast diversity of mouse lines is already available for 
studying retinal diseases and that new transgenic mice can be easily generated.  
Since mutations in the loci encoding the A3 and B3 CNG subunits are the most common 
mutations identified in ACHM-patients (Kohl et al., 1998, Sundin et al., 2000), the most widely 
used ACHM mouse models are mice with a knock out (KO) of the corresponding genes Cnga3 
and Cngab3, respectively (Biel et al., 1999, Ding et al., 2009). Like human patients these mice 
lack (Cnga3 ko) or have strongly compromised (Cngb3 KO) cone function by birth as detected in 
Electroretinography (ERG) measurements (Figure 1.10D) (Biel et al., 1999, Ding et al., 2009). 
Comparing these two mouse models one key-difference is the residual cone function observed in 
the scotopic (cone) ERG recordings of Cngb3 KO mice while Cnga3 KO mice show no 
recordable cone ERG. Residual cone-ERG in Cngb3 KO mice is a result of a small number of 
homomeric CNGA3 channels in the membrane of the outer segments (Ding et al., 2009). 
Another characteristic difference of these two mouse models is the speed of degeneration. The 
loss of the Cnga3 subunit leads to a faster progression of cone death compared to Cngb3 loss 
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(Arango-Gonzalez et al., 2014). Moreover the degeneration process is not equally progressing in 
the retina of Cnga3 KO mice. Ventral cones degenerate more rapidly compared to dorsal ones 
(Figure 1.10 A/B). The retina of a three month old Cnga3 KO mouse in comparison to a wild 
type retina clearly illustrates the gradient of degeneration (eGFP positive cones in Figure 1.10 
A/B).  
In mice eye opening occurs between 12 and 13 days after birth (P12-13) but the maturation of 
the eye is not completed until one week after eye opening (P19-21) (Okawa et al., 2014, Hoon et 
al., 2014).The peak of cell death in Cnga3 KO mice was initially determined at three weeks after 
birth (P21) (Michalakis et al., 2005) but a more recent paper suggests the peak to be rather 
around P35 (Fig 1.10C) (Arango-Gonzalez et al., 2014).  
 
 
 
B 
C 
D A 
Figure 1.10: Characteristics of the 
degeneration in the Cnga3 KO mouse 
model: The degeneration of cones (eGFP) is 
not equally progressing in the retina of Cnga3 
ko mice (A). The ventral located cones 
degenerate more rapidly compared to dorsal 
cones as seen in a confocal laser scanning 
ophthalmoscopy (cSLO)-recordings of a 3-
month old Cnga3 KO mouse (B). Two weeks 
after birth TUNEL-positive cones can be 
detected but the peak of cell-death is rather 
between P30 and P35 (C, adapted from 
(Arango-Gonzalez et al., 2014). Cone 
photoreceptors are non-functional from birth 
and thus no scotopic (cone) ERG can be 
detected (D, adapted from Biel et al., 1999) 
Cnga3 ko wildtype 
cones 
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 Gene therapy for Achromatopsia  
Over the past ten years gene therapy approaches received a lot of attention in ophthalmology 
research and became an important tool for research (Schon et al., 2013, Kaufmann et al., 2013, 
Zulliger et al., 2015). With its exceptional immune privilege and the feasible accessibility the eye 
is an ideal experiment subject for gene therapy approaches (Medawar, 1948, Zulliger et al., 2015, 
Klassen, 2016, Willett and Bennett, 2013). Compared to other tissues, like for example the brain, 
the retina is easy to access for viral application by minimal-invasive procedures and specific 
regions or specific cell-types can be easily targeted by viral particles. For retinal gene delivery 
recombinant adeno-associated viruses (rAAVs) seem to be the most promising tool for gene 
delivery given their low immunogenicity and their high efficacy profile (Figure 1.11) (Boye et al., 
2013, Carvalho and Vandenberghe, 2015, Trapani et al., 2014). 
There are already several gene therapy approaches using rAAVs to cure inherited retinal diseases. 
In 2010 Michalakis et al. showed distinctive visual improvements in Cnga3 KO mice after gene 
therapy. rAAVs expressing mouse Cnga3 under a cone-specific promoter improved and 
maintained the visual ability of mice for at least eight months after treatment (Michalakis et al., 
2010, Michalakis et al., 2012). This crucial work provided evidence that CNGA3 
supplementation might be a potential treatment for human ACHM patients (Mamasuew et al., 
2010, Michalakis et al., 2012). In 2012 another study confirmed that Cnga3-gene therapy can be 
successful in a naturally occurring Cnga3-mutation of the cpfl5 mouse (Pang et al., 2012, Pang et 
al., 2010). In two other studies Cngb3 KO mice and a canine Cngb3 ACHM model were treated 
by gene therapy (Carvalho et al., 2011, Komaromy et al., 2010). These studies demonstrate that 
also other genetic loci are suitable for gene replacement with Cngb3. An age-dependency was 
Figure 1.11 Recombinant Adeno-
associated virus (rAAV) gene delivery has 
become an important tool of ophthalmic 
research due to their excellent efficacy, 
their good immune response and long-
term success in retinal gene delivery. 
Furthermore rAAVs have a promising 
safety profile. They stay predominantly 
episomal after transduction and still 
achieve strong expression rates of their 
target gene. 
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observed during treatment of CNGB3-dependent ACHM (Carvalho et al., 2011, Komaromy et 
al., 2010) which might limit the application of such AAV-mediated gene replacement therapy to 
younger patients. Thus there is a limited time window where treatment can be successful.  
Additionally, the newly discovered Cnga3 sheep breed from Israel showed a recovery of cone 
function after treatment with either human or mouse CNGA3 packed in an AAV5 serotype 
applied by unilateral subretinal delivery. Most importantly cone function was maintained in 
treated sheep for over three years (Ezra-Elia et al., 2014, Banin et al., 2015). 
All these studies show highly promising data for gene therapy treatment in the retina. However 
when the first clinical trial of ophthalmic research completed clinical phase I and II the results 
were rather disappointing (Cideciyan et al., 2013, Jacobson et al., 2015a). Based on numerous 
animal experiments, a clinical study aimed to treat the retinal degenerative disease 
congenital amaurosis (LCA) (Acland et al., 2005, Acland et al., 2001, Dejneka et al., 2004, 
Jacobson et al., 2005, Narfstrom et al., 2005, Narfstrom et al., 1989). Even though all clinical 
trials reported visual improvements and no severe side-effects in patients, the significance of 
improvement and the efficacy differed vastly (Boye et al., 2013, Cideciyan, 2010). One study 
even reported a decline in previously detected visual improvements during follow-up 
examinations (Bainbridge et al., 2015, Jacobson et al., 2015b) and other studies detected that 
photoreceptor degeneration did not decrease in treated patients (Cideciyan et al., 2013, Jacobson 
et al., 2015a, Cideciyan, 2010). These results clearly emphasize the medical need for 
neuroprotection before and during retinal gene therapy  
Already studies in Cngb3 animals showed that a decisive factor for the success of gene-therapy is 
the time point of treatment (e.g. age) indicating that the ongoing degeneration diminishes the 
success of gene therapy (Carvalho et al., 2011, Komaromy et al., 2010). Accordingly a very 
important issue of retinal degeneration research is to arrest photoreceptor cell death and increase 
the time window where gene-therapy treatment is successful. 
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 Aim of this thesis 
 
The mechanisms leading to photoreceptor death are poorly understood in Achromatopsia. The 
time window where gene therapy is successful seems to be limited due to the ongoing 
photoreceptor cell death. Thus aim of this thesis is to arrest cell death in order to extent the time 
window where treatment is efficient and also to protect photoreceptors during and after gene 
therapy treatment. In order to understand the signalling leading to cell death in Achtomatopsia, 
the following questions were addressed in this thesis: 
 
1.) Is there an imbalance of cGMP homeostasis in Cnga3 KO mice? 
cGMP is already shown to accumulate in retinal degeneration mouse models and has 
been suggested to have a crucial role in the process of photoreceptor loss (Xu et al., 2013, 
Paquet-Durand et al., 2009, Michalakis et al., 2010, Bowes et al., 1990). Therefore, in 
this study cGMP was detected at various time points of maturation and degeneration in 
the retina of Cnga3 KO mice.  
 
2.) Does cGMP influence the degeneration process or is it only a bystander effect? 
To unravel the role of cGMP levels in the degeneration process, cGMP-production was 
decreased and the involvement of direct effectors of cGMP were further examined. 
 
3.) Which proteins are involved in the signalling pathway leading to cell death?  
Finally the study also aimed at identifying the signalling pathway downstream of cGMP 
that ultimately triggering a cell-death signal. 
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 Materials and Methods 
 Animals 
All mice used were on a mixed background. cGK/Cnga3 double and triple knockout mice 
(cGKI/Cnga3; cGKII/Cnga3ko; cGKI/cGKII/Cnga3ko) were generated by cross-breeding Cnga3 
KO mice on a C57BL/6 N background (Biel et al., 1999) with cGKI or cGKII KO mice on a 
129/Sv genetic background (Weber et al., 2007, Pfeifer et al., 1996). The resulting offspring were 
identified by genotyping (PCR). Age matched Cnga3 KO and wild type mice with the same 
mixed background were used for comparison. For in vivo tracing of cones afte shRNA-
application, Cnga3 KO mice on a were also crossbred with RgeGFP mice (Ikawa et al., 2003).  
Mice were given ad libitum access to food (Ssniff; regular feed: R/M-H, breeding feed: M-Z 
Extrudat) and water. Mice were maintained on a 12 h light/dark cycle. All procedures concerning 
animals were performed with permission of the local authority (Regierung von Oberbayern). Day 
of birth was considered as postnatal day 1 (P1). 
 
 Chemicals, solutions and buffers  
All chemicals used were obtained by Bio-Rad, Fluka, Merck, Roth and Sigma-Aldrich if not 
mentioned otherwise. The quality was "pro analysis" or "for molecular biological use". For all 
solutions high pure and deionised water was used (Milli-Q Plus System, Milli-pore). In 
experiments that required a high purity all solutions were autoclaved (Sterlisator, Münchener 
Medizin Mechanik).  
 
 Genotyping 
Genotyping was performed by polymerase chain reaction (PCR). The following genetic 
constitutions: knock out (ko), wild type (wt) and heterozygous (hz) were identified for the 
following gene-loci Cnga3, Prkg1 (cGKI) and Prkg2 (GKII). For the smooth muscle knockin of 
cGKI (SM1) and the RG-specific knock in of eGFP (RgeGFP knock in (ki) or wildtype was 
determined. 
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Mouse ear tissue samples were digested with 600µl of 50mM NaoH at 95°C for at least 15 Min. 
Samples were shock frozen in liquid nitrogen and again heated for ~5 Min. at 95°C. Subsequently 
probes were vortexed and 50µl 1mM Tris-Hcl was added for neutralization. Tissue lysates were 
then used as DNA-templates for PCR reactions with the following primer-sets: 
primer: 
Table 2.1: Primer used for genotyping. All primers used were produced by Eurofins MWG. 
Gene Primer Sequence 
Cnga3 mCG76R (rev) caa gtt ccc tat cct gaa cac g 
Cnga3 mCG19F (for) ctt agg ttt cct tga ggc aag g 
Cnga3 NeoPR (rev) gcc tgc tct tta ctg aag gct c 
cGKII AV3R (rev) att aag ggc cag ctc att cc 
cGKII AV9R (rev) ctg ctt aat gac gta gct gcc 
cGKII E2FB-AV (for) ggt gaa gtt tta ggt gaa acc aag 
Cngb1 PSHV6bR (rev) gcc cag act aga aca caa gtc 
Cngb1 PSHV9R (rev) 
 
cac agc cat tac aca tag cag tg  
 
Cngb1 PSHV8F (for) cct cat gca tgc gac ctg aaa t 
cGKI RF53 (rev) cct ggc tgt gat ttc act cca 
cGKI RF125 (for) gtc aag tga cca cta tg 
cGKI RF118 (for) aaa tta taa ctt gtc aaa ttc ttg 
 
Table 2.2: Pipetting scheme of PCR for genotyping GoTaq G2 polymerase as well as 5× GoTag Buffer was 
purchased from Promega. 1 mM dNTP solution was made from 10mM dNTP Mix (Thermo Scientific) by diluting 
it in a ratio of 1:10. 
Volume 
(µl) 
Component 
2 Tissue lysate 
1,25 Primer forward (wt) 
1,25 Primer Primer forward (ko/ki) 
1,25 Primer reverse (common) 
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5 GoTaq Buffer (5x), Promega 
4 dNTPs (1mM) 
10,125 dl H2O 
0.125 Taq-Polymerase 
 
Table 2.3: Cycle conditions for genotyping 
utilized for PCR-amplification under the following cycle conditions. 
 Time 
 Cnga3/ 
eGFP 
 
cGKI/SMI 
 
cGKII 
 
 
Initial 
denaturation 
5 min 
 95°C  
95°C 
 
95°C 
 
 
Denaturation 30 sec 
30
x 
95°C 
40
x 
95°C 
11
x 
95°C 
28
x 
95°C 
Annealing 30-45 sec 57°C 55°C 57°C 57°C 
Elongation 30 sec 72°C 72°C 72°C 72°C 
Final elongation 7 min  72°C  72°C    72°C 
 
 Agarose gel electrophoresis 
Gel-electrophoretic separations for the genotyping were performed on 2 % (w/v) agarose gels. To 
pour a gel, the corresponding amount of agarose (peqGOLD Universal-Agarose, Peqlab) was 
microwaved along with the appropriate volume of 1× TBE buffer until the agarose was 
completely dissolved. For visualization under ultraviolet light (Gel Doc 2000, Biorad) PeqGreen 
(peqlabs) solution (final concentration in the gel: 0,025µl/ml) was added. PeqGreen binds DNA 
and fluoresces at UV-light irradiation. 
PCR samples were loaded into the sample wells. One additional well was loaded with the 
molecular weight ladder (GeneRuler 1 kb Plus DNA Ladder, Thermo Scientific). 1× TBE buffer 
was used as running buffer. 
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 Retina dissection 
Mice were euthanized with Isofloran and then sacrificed. Eyes were protruded out of the orbit 
(exophthalmus) and fixed with curved forceps. With a sharp blade, the cornea was incised and by 
pulling the forceps the retina, the lens and the vitreous body are smoothly removed from the eye. 
After rinsing in cold 0.1M PB and removing the lens and remaining RPE-cells, the tissue was 
transferred into .a 1.5 ml reaction tube, shock frozen in liquid nitrogen and either directly 
processed for RNA or protein extraction or stored at -80°C until further use. 
 
 RNA extraction  
Total RNA extraction was performed using the RNeasy-Mini Kit (Qiagen) according to the 
μl RLT Buffer was added to two retina of one animal 
(approximately 20 mg tissue). The tissue was disrupted and homogenized using a 27G needle 
(Sterican) and a 1 ml syringe (Terumo). The supernatant was carefully transferred to a new 
microcentrifuge tube. 350 μl of 70 % ethanol was added to the lysate, and mixed well by 
pipetting. The sample, including any precipitate, was transferred to an RNeasy MinElute spin 
column (Qiagen). The sample was centrifuged for 15 s at 10.000 rpm in a microcentrifuge 
(Fresco 17 microcentri-fuge, Thermo Scientific). Next, 350 μl Buffer RW1 was added to the 
RNeasy MinElute spin column. The sample was again centrifuged for 1 min at 10.000 rpm and 
10 μl DNase I stock solution was added to 70 μl Buffer RDD. The DNase I incubation mix (80 
μl) was added to the RNeasy MinElute spin column membrane, and placed on the benchtop at 
room temperature for 15 min. Next 350 μl Buffer RW1 was added to the RNeasy MinE-lute 
spin column and centrifuged for 15 s at 10.000 rpm. 500 μl Buffer RPE was added to the spin 
column and centrifuged for 15 s at 10.000 rpm. Next, 500 μl of 80 % ethanol was added. The 
RNA was eluted by adding 12 μl RNAse-free water directly on the centre of the spin column 
membrane and centrifuging for 1 min at full speed. 
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 cDNA synthesis  
Reverse Transcription (RT) was performed using the RevertAid First Strand cDNA Synthesis Kit 
(Thermo Scientific; cat.nr. K1691
following reagents were added into a sterile, nuclease-free tube on ice in the indicated order:  
 
cDNA synthesis mixture (total volume: 20 μl): 
Template RNA/total RNA:    200 ng  
primer: oligo (dT)      1 μl  
random hexamer primer    1 μl  
water, nuclease-free / add volume to   12 μl  
5 x Reaction buffer      4 μl  
10 mM dNTP Mix     2 μl  
RiboLock RNase Inhibitor (20 u/μl)    1 μl  
RevertAid Reverse Transcriptase (200 u/μl)  1 μl  
 
The sample was mixed gently, centrifuged and incubated for 5 min at 25 °C followed by 60 min 
at 42 °C. The reaction was terminated by heating at 70 °C for 5 min. The cDNA was used 
directly for qPCR or stored at - 80 °C for long-term storage.  
 
 Microarray analysis  
Microarray experiments of retinal tissue were performed at two different ages (PW4 and PW8) 
comparing gene expression of Cnga3 KO and wild-type animals using an Affymetrix platform 
labeled cRNA of the retinas of 
three wild-type and three Cnga3 KO mice were hybridized on Affymetrix Mouse Genome 430 
2.0 Arrays. A probe-level summary was determined using the Affymetrix GeneChip Operating 
Software using the MAS5 algorithm. Normalization of raw data was performed by the Array 
Assist Software 4.0 (Stratagene, La Jolla, CA, USA), applying the GC-robust multichip average 
(RMA) algorithm. Significance was calculated using a t-test without multiple testing correction 
(Array Assist software), selecting all transcripts with a minimum change in expression level of 1.5-
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fold together with a p value <0.05. The heatmaps were generated using Multi Experiment Viewer 
Software (MeV v4.8.1.).  
 
 Gene regulation networks  
Gene regulation networks were generated by Ingenuity Pathways Analysis (IPA) 8.8 
(http://www.ingenuity.com). For that purpose, data sets containing gene identifiers and the 
corresponding expression and significance values were uploaded into the application. These 
genes, called Focus Genes, were overlaid onto a global molecular network developed from 
information contained in the Ingenuity Pathways Knowledge Base. Networks of these Focus 
Genes were then algorithmically generated based on their connectivity.  
 
 Functional analyses  
Ingenuity functional analysis identified the biological functions and/or diseases that were most 
significant to the data set. Genes from the data set that met the negative logarithmic significance 
cut-off of five or higher, and were associated with biological functions and/or diseases in the 
to calculate a p value determining the probability that each biological function and/or disease 
assigned to that data set is due to chance alone  
 
 Real-time quantitative PCR (qPCR)  
qPCR was performed on an Applied Biosystem LightCycler using SybrGreen QPCR Master mix 
(Applied Biosystem).  
CT values were determined by the applied Biosystem BioOne Software using the following fast 
cycle protocol:  
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Table 2.4 Cycle conditions for real-time quantitative PCR (qPCR) measurements.  
 °C time 
UDG activation  50 02:00 
pre-incubation  95°C 00:05:00 
40 
cycles 
Pre-incubation 95 00:00:05 
primer dependent 
annealing 
55-60 00:00:05 
amplification 60 00:00:30 
Melting 
curve  
 95  00:00:05 
 65  00:01:00 
continuous 98  5-10 
 
Expression levels of each sample were detected in duplicate reactions. Three different biological 
replicates were analysed in duplicates and normalized to the expression of the housekeeping gene 
aminolevulinic acid synthase (ALAS). Relative quantification was determined by the method 
described by Pfaffl delta delta Ct (2002). The data were presented as mean ± SEM.  
 
 Retina dissection (IHC) 
Mice were sacrificed and each eyeball was marked temporally by a glowing needle to remember 
the orientation. Eyes were protruded out of the orbit (exophthalmos) and removed with a scissor. 
For prefixation, eyes were pierced at the ora serrata using a cannula (21G, Sterican, B. Braun) and 
incubated in 4 % paraformaldehyde (PFA) on ice for 5 min. The cornea was removed by 
crosscutting along the ora serrata with a micro-eye spring scissor (Mini Vanas, blade 3 mm, 
Frohnhäuser) under a dissecting/stereo-scopic microscope (Stemi 2000, Zeiss). The temporal 
mark was preserved by placing a small incision into the eyecup. Subsequently, cornea, lens and 
vitreous body were dislodged and the remaining eyecup was fixed in 4 % PFA on ice for 45 min. 
Subsequently eyes were washed thrice in 0.1 M PB and dehydrated overnight in 30 % sucrose for 
cryopreservation. Finally, the eyecup was embedded in tissue freezing medium (Electron 
Microscopy Sciences) and frozen on dry ice. Tissue was kept at -80°C for at least 24 h before 
further processing or stored at -80°C until use. 
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Table 2.5 Composition of solutions used for retina dissociation. 
0,1 M PB Na2HPO4 x 2 H2O 28.48 g  
NaH2PO4 x H2O 5.52 g  
H2O ad 2 l  
pH 7.4, stored at 4 °C.  
4 % PFA 
(in PB)  
 
Paraformaldehyd (Merck) 6 g  
0.1 M PB ad 150 ml  
dissolved at 60 °C and sterile filtered using a 25mm syringe filter (VWR). 
Aliquots were stored at  20 °C.  
30 % 
sucrose 
solution 
(in PB) 
sucrose 30 g  
0.1 M PB ad 100 ml  
sterile filtered using a 25mm syringe filter (VWR) and stored at - 20 °C. 
 
 Retinal cryosections  
For retinal cryosections embedded eyecups in tissue freezing medium were cut into 10 μm 
cryosections by a kryostat (Leica CM3050 S, Leica Biosystems) and mounted on glass object 
slides (Super Frost Plus, Menzel). Cryosections were dried at room temperature and stored at - 20 
°C until further processing.  
 
  Immunohistochemistry  
Retinal cryosections (10 μm) were thawn for at least 10 min at room temperature and then re-
hydrated with sterile 0.1 M phosphate buffered (PB) for 10 min. For post-fixation slides were 
incubated with 4 % para-formaldehyde (PFA) in 0.1 M PB, pH 7.4 for 10 min at room 
temperature (RT). After washing thrice with 0.1 M PB for 5 min, cryosections were incubated 
with the primary antibody-mixture containing 5 % chemiblocker (Millipore) and 0.3 % Triton 
X-100 in sterile 0.1 M PB for 3 h at RT or overnight at 4 °C. Subsequently they were washed 
thrice with 0.1 M PB for 5 min. and then incubated with the secondary antibody in sterile 0.1 M 
PB with 2 % CB for 1.5 h at RT. 
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The following secondary antibodies were used (catalogue number and working dilutions in 
brackets):  
Alexa-Fluor 488 goat anti-mouse IgG (H+L) (1:800, Thermo Fisher Scientific, #A-11001)  
-rabbit IgG (1:400, Jackson ImmunoResearch Laboratories)  
2 donkey anti-sheep IgG (1:200, Jackson ImmunoResearch Laboratories)  
Cell nuclei were counterstained with Hoechst 33342 (5 μg/mL, Invitrogen) and sections were 
mounted with aqueous mounting medium (PermaFluor, Beckman-Coulter).  
  
Table 2.6 Antibodies used for Immunohistochemical stainings. 
Antibody company Dilution IHC 
sheep anti-cGMP 
 
Purchased from Prof 
Steinbusch, Maastricht 
University (Tanaka et 
al., 1997) 
1:500 
rabbit/guinea pig anti-
glycogenphosphorylase 
(glypho) 
Purchased from Prof 
Hamprecht, University 
of Tübingen. 
1:1000 
rabbit anti-cGKI alpha 
kindly provided by F. 
Hoffmann 
1:100 
rabbit anti-cGKI beta 
kindly provided by F. 
Hoffmann 
1:100 
rabbit anti-γ-H2AX abcam 1:1000 
goat anti-Atr Santa Cruz 1:200 
mouse anti-Npm1 Cell-Signalling 1:1000 
Atr p428 Cell Signalling 1:1000 
 
Materials and Methods 
37 
Retina morphology und number of cones were analysed using a Zeiss Axioscope epifluorescence 
microscope equipped with a HBO 100 mercury arc lamp, appropriate filters equipped with an 
MRc ccd camera (Zeiss). Laser scanning confocal micrographs were collected using a Leica SP8 
microscope (Leica). 
 
 Terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL)-assay 
Retinal cryosections stored at -20°C were thawn and re-hydrated with sterile 0,1M PB for 5 
minutes. Sections were fixed with 4 % PFA/PB for 10 minutes and then permeabilized with 
0,25 % Triton X in PB for 20 min. For co-staining with hmc sections were permeabilized with 
2N HCl instead. Slices were washed with deionized water and a positive control was prepared by 
DNAse incubation for 30 minutes. Slices were washed again with deionized water and 
preincubated with TdT reaction buffer for 10 minutes at room temperature. The TdT reaction 
cocktail, containing EdUTP and TdT, was prepared and added on each sections. Coverslips were 
either incubated over night at room temperature or for one hour at 36°C.  
After incubation cryosections were washed twice with 3 % BSA in PB for two minutes. The 
Click-it reaction cocktail, containing Alexa Fluor 647, was prepared, added on the slices and 
incubated for 30 minutes at room temperature protected from light. The mixture was removed 
and the slides were washed with 3 % BSA in PB once more for 5 minutes. Following TUNEL 
staining a costaining with hmc was performed as described in section 2.14 primary and secondary 
antibodies were incubated. Last coverslips were stained with Hoechst 33342 (5µg/ml) for 5 
minutes protected from light and mounted as described in 2.14. 
 
 Cloning 
For cloning techniques AAV-Vectors were used carrying an Ampicillin resistance (AmpR) for 
selection of recombinant bacterial cells. The expression cassette in these plasmids is framed by 
two inverted terminal repeats (ITR) encoding all cis-acting elements for efficient replication (rep) 
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and packaging (cap) of rAAVs in the presence of two helper plasmids described in the AAV-
production. The packaging capacity of an AAV-Vector is approximately 5.1 kilobase pairs (kb). 
For ubiquitous expression a pAAV2.1 cis plasmid was used with the cytomegalovirus (CMV) 
promoter, capable of driving heterologous gene expression in mammalian cells. Other promoters 
used in this study were the rod-specific mouse rhodopsin promoter (mRho) and the cone-specific 
short-wavelength opsin promoter (mSWS) making tissue-specific expression possible (Koch et al., 
2012, Michalakis et al., 2010). Downstream of the gene of interest an enhanced green fluorescent 
protein (eGFP) was cloned as a report gene. eGFP and the gene of interest were separated by the 
- -region, ensuring equimolar levels of both genes (Robertson et al., 1985, 
Donnelly et al., 2001).. Finally a hepatitis virus posttranscriptional regulatory element (WPRE) 
was cloned into the vector to enhance gene expression.  
For shRNA expression a modified pSub-Vector (Samulski et al., 1987) was used with a PolIII 
promoter, the so called U6-promoter was used. Additionally a mcherry was present as a reporter 
gene downstream of a phosphoglycerate kinase 1 (PKG) promoter. Again WPRE was cloned for 
enhanced expression.Cloning of constitutive active cGKI 
 
 Cloning of the catalytic domain of cGKI 
The catalytic domain of cGKI was cloned into a recombinant Adeno-associated-virus (rAAV) 
vector for virus production (Ruth et al., 1997, Boerth and Lincoln, 1994, Deguchi et al., 2004).  
By an overlap-PCR approach the insert for the pAAV2.1-sc-SWS-eGFP vector was generated. All 
primers used were synthesized and purchased at MWG Eurofins. The first educt for the overlap-
PCR was amplified from pMT3-cGKIbeta (obtained from Hofmann, REF) using a forward 
primer binding at the beginning of the catalytic domain of cGKIbeta with a compatible 
restriction site (BamHI): 5'-TTGGATCCACCATGGCATATGAAGATGCAGAAGCTAAG-
3'. The reverse primer on the other hand binding at the end of the catalytic domain containing 
the first fracture of the 2A-region 
(GGATCCGGAGCCACGAACTTCTCTCTGTTAAAGCAAGCAGGAGACGTGGAAGAAA
ACCCCGGTCCT) 
5'-GTCTCCTGCTTGCTTTAACAGAGAGAAGTTCGTGGCTCCGGATCCGAAGTCTATGT
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CCCATCCTGAG-3'. The second educt was generated by a primer providing the other part of 
the 2A-peptide and  
5'-GCCACGAACTTCTCTCTGTTAAAGCAAGCAGGAGACGTGGAAGAAAACCCCGGTCCT
ACTAGTATGGTGAGCAAGGGCGAGGA-3' and a primer binding at the end of the eGFP-
sequence 5'-TTACTTGTACAGCTCGTCCATG-3' of the pAAV2.1-sc-SWS-eGFP-vector. 
Finally the insert was generated out of these two overlapping PCR-products by combining both 
products and the PCR-primer 5'-
TTGGATCCACCATGGCATATGAAGATGCAGAAGCTAAG-3' and 5'-
TTACTTGTACAGCTCGTCCATG-3'. The final PCR-product was then restricted with the 
compatible restrivtion enzymes and ligated into the linearized vector (pAAV2.1-sc-SWS-eGFP) 
to obtain pAAV2.1-sc-SWS-cAcGKI-2A-eGFP 
 
Figure 2.1 Recombinant Adeno-associated virus (rAAV) vector Between the ITR-regions of a vector for viral 
production the constitutive active cGMP-dependent kinase (cAcGK) was cloned behind the rod-specific promoter 
rhodopsin. An enhanced green fluorescent protein (eGFP) served as a report gene. The gene of interest and eGFP were separated 
by - -region, ensuring equimolar levels of both genes. A hepatitis virus posttranscriptional regulatory element 
(WPRE) was cloned into the vector to enhance gene expression and the polyadenylation signal (pA) of the bovine growth 
hormone (BGH) was added for polyadenylation. 
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 Cloning of shRNAs 
For the generation of double stranded shRNAs 1 µl of each single stranded oligo (both sense and 
anti-sense strands with compatible restriction site overhangs at 3 mg/ml) in 90 µl dl water and 10 
µl of 10x-PCR-buffer. Oligo mix was heated to 95°C for 10 min, and slowly cooled to RT and 
immediately used for ligation. 
Gucy shRNA: 
Ccggtgcccatgatgtctataatcaagagttatagacatcatgggcaccgttttt 
Validated sequence adapted from (Tosi et al., 2011) 
cGKII shRNA: 
CCGAACCTATGACCTCAACAAAtcaagagTTTGTTGAGGTCATAGGTTCGTTTTTGAT 
For validatin see section 2.19 
 
cGKII shRNA 
CCGCTTGGAAGTGGAATACTATCAAGAGTAGTATTCCACTTCCAAGCTTTTTGAT 
 
 Restriction analysis 
Restriction enzymes were purchased form the companies New England Biolabs (NEB) and 
Thermo Fisher Scientific (formerly Fermentas). The reaction conditions were conducted 
according to the respective manufacturer's protocols. The amount of DNA used for cloning was 
3-5 μg, whereas 0.5 μg of DNA or 2 μl of minipreparation of plasmid DNA (see 2.2.8) were used 
for restriction analysis. 
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Figure 2.2 Recombinant Adeno-associated virus (rAAV) vector carrying a shRNA. Between the ITR-regions of 
a vector for viral production a shRNA was cloned behind the U6 promoter. A mcherry protein served as a reporter 
downstream of a phosphoglycerate kinase 1 (PKG) promoter. A hepatitis virus posttranscriptional regulatory element (WPRE) 
was cloned into the vector to enhance gene expression and the polyadenylation signal (pA) of the bovine growth hormone (BGH) 
was added for polyadenylation.. 
 
 Ligation 
Ligation was performed using T4 DNA ligase (NEB). The vector to insert ratio was between 1:3 
to 1:5. Therefore, the amount of the vector and insert DNA fragments was calculated for each 
ligation reaction. Pipetting scheme and reaction conditions were applied according to the 
manufacturer's manual. The reaction was incubated overnight at 16 °C. 
 
 Transformation  
100 μl aliquots of chemically treated, competent β10 Escherichia coli (E. coli) strain stored at -80 
°C were thawed on ice and then transformed with 5-10 µl ligation reactions. The bacteria 
suspension was gently mixed by tapping at the tube wall and was incubated on ice for 10-20 min. 
A subsequent heat shock was performed at 42 °C for 45 sec in a heat block and cells were chilled 
1
pSub-U6-shRNA-PGK-mcherry-WPRE
6500bp
ITR
U6
WPRE
shRNA
PGK
mcherry
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on ice for another 10 min. The cell suspension was plated on the LB(+) selection agar plate 
containing 100 μg/ml ampicillin (resistance provided by the used plasmids) and was incubated 
overnight at 37 °C. 
 
-LB(+) medium: peptone 10 g, NaCl 5 g, yeast extract 5 g, glucose 1, H2O ad 1 l; adjust pH to 
7.2-7.5 and autoclave 
-LB(+) agar: agar 15 g, LB(+) medium ad 1 l, ampicillin 100 mg 
 
  Inoculation of bacterial cells and mini preparation of plasmid DNA 
After overnight incubation bacterial clones were picked from the LB-plate and incubated in 3-
6 ml LB(+) medium with 100 μg/ml ampicillin at 37 °C with 225 rpm for at least 16 hours. The 
suspension was centrifuged at 3500 rpm at room temperature (RT) for 10 min and the 
supernatant was removed. The pellet was re-suspended in 250 μl MP1 buffer and transferred into 
2 ml Eppendorf tubes. For Lysis 250 μl MP2 buffer was added, the cell suspension was inverted 5 
times and further incubated for at least 5 min at RT. With 250 μl MP3 buffer the lysis-mixture 
was neutralized over a time frame of 5 min and inverted 5 times. The suspension was then 
centrifuged at 13,000 rpm at 4 °C for 15 min. The supernatant containing the plasmid DNA was 
transferred into a fresh 1.5 ml Eppendorf tube. To precipitate the DNA, 525 μl isopropanol was 
added to the mix. After vortexing, the mixture was centrifuged at 13,000 rpm and 4 °C for 15 
min. Subsequently, the pellet was washed with 70 % (v/v) ethanol by centrifugation at 13,000 
rpm and 4 °C for 5 min. The supernatant was discarded and the pellet was air-dried before 
resuspension in 30 μl of H2O. For large scale and high purity plasmid isolation, PureLink® 
HiPure Plasmid Midiprep or Megaprep Kit (Invitrogen) was used, following the instructions 
 
Subsequently every plasmid was sequenced by Eurofins MWG Operon to verify the cloning. 
Samples and corresponding primers were diluted to concentrations proposed by the company. 
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Buffers: 
-MP1 Buffer (Resuspension buffer): Tris 6.06 g; EDTA 3.72 g; RNAse A 100 mg; H2O ad 1 l; 
adjust pH to 8.0 with 37 % HCl 
-MP2 buffer (Lysis buffer): NaOH 8 g; 10 % (w/v) SDS solution 100 ml; H2O ad 1 l 
-MP3 buffer (Neutralization buffer): 3 M potassium acetate pH 5.5 500 ml; H2O ad 1 l 
 
 AAV production 
The two helper plasmids used for the generation rAAVs were pAD Helper plasmid and 
pAAV2/8-YF rep/cap plasmid which contains rep gene of serotype AAV2 and cap gene of 
serotype AAV8 for enhanced specific transduction of photoreceptors (Allocca et al., 2007; 
Vandenberghe and Auricchio, 2012). The serotypes contain mutations (YF) substituting tyrosine 
(Y) with phenylalanine (F) residues at exposed sites of the capsid surface to allow for a high 
transduction efficiency in host retinal cells (Petrs-Silva et al., 2009; Petrs-Silva et al., 2011). 
 
 Transfection and harvest 
HEK293T cell line was used for transfection of the pAAV2.1 vector plus the helper plasmids 
pAD Helper and pAAV 2/8 (YF) via calcium phosphate transfection method as described in 
chapter 2.3.2. In addition to the regular components of the transfection reagent, dextran 500 and 
polybrene were added to achieve higher transfection efficiencies (Wu and Lu, 2007). 24 h before 
transfection, confluent 15 cm dishes of HEK293T cells were split 1:6 into 15x 15 cm dishes for 
each construct. The following two equations were used to calculate the necessary amount of pAD 
Helper and pAAV2/8 for the transfection solution: 
 
*pAD Helper:  𝑥µ𝑔 =
DNA concentration of AAV plasmid
MM of AAV plasmid ∗ MM of pAD helper
  
**pAAV2/8 (YF)  𝑥µ𝑔 =
DNA concentration of AAV plasmid
MM of AAV plasmid ∗ MM of pAAv 2/8  YF
 
MM = molar mass of double stranded plasmid 
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Transfection solution:  
pAAV2.1 vector 270 μg 
pAD Helper  calculated * μg 
pAAV 2/8 (YF)  calculated ** μg 
2.5 M CaCl2 1.75 ml 
8 mg/ml polybrene  17.5 μl 
10 mg/ml dextran 1.75 ml 
H2O  ad 17.5 ml 
 
The transfection solution was vortexed while adding 17.5 ml 2x BBS dropwise before adding to 
all 15 dishes with each 70-80 % cell confluence. Medium replacement was done 24 h post-
transfection. After another 24 h, cells where harvested by scraping them with a cell scraper from 
each 15 cm dish and collecting cell suspensions from all dishes in a 500 ml centrifuge tube. The 
cell suspension was centrifuged at 2000x g and 4 °C for 15 min (4000 rpm in a J2-MC Beckman 
centrifuge using a JA-10 rotor). The medium was decanted from the cell pellet before 
resuspending in 7.5 ml lysis buffer and subsequent transferring into a 50 ml polystyrene tube. 
Lysis buffer for AAVs: NaCl 150 mM, Tris-HCl pH 8.5 50 mM, sterile filtrate 
 
 Purification of rAAVs via iodixanol gradient centrifugation 
The cell suspension was shock-freezed in liquid nitrogen and thawed at 37 °C in a water bath for 
three times. Benzonase was added to the thawed cell suspension to a final concentration of 50 
U/ml and the suspension was incubated at 37 °C for 30 min. The cells were pelleted via 
centrifugation at 2000x g and 4 °C for 25 min and the virus-containing supernatant was 
transferred into a Beckman Quick-Seal polypropylene tube (Beckman). The virus-containing 
phase was underlain with 7 ml 15 % iodixanol, followed by 5 ml 25 %, 5 ml 40 %, and at last by 
6 ml 60 % iodixanol. Using a sterile, long glass pipette and a Gilson MINIPULS3 pump the 
iodixanol underlayers were made without mixing of the layers. The polypropylene tubes were 
balanced with PBS-MK before sealing them with the Beckman Tube Topper. Gradient 
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centrifugation was carried out at 361,000x g and 18 °C for 1 h 45 min (70,000 rpm in an 
Optima LE-80K Beckman ultracentrifuge using a 70 Ti rotor). In the following step, the tube 
was pierced multiple times at the top near the seal for pressurization. To collect the 40 % phase 
containing the virus, a 21-gauge needle with a 5 ml syringe was used to pierce the tube through 
the side at the lower end of the 40-60 % interface. Approximately 5 ml of the 40 % phase were 
collected until the interface was close below the 25 % phase:  
 
Table 2.7 Composition of solutions used for viral production 
Tween/PBS-MK 10x PBS 50 ml 
1 M MgCl2 500 μl 
2.5 M KCl 500 μl 
Tween 20 0.014 % (v/v) 
H2O ad 500 ml, sterile filtrate 
15 % iodixanol 
 
10x PBS 5 ml  
1 M MgCl2 50 μl 
2.5 M KCl 50 μl 
5 M NaCl 10 ml 
Optiprep 12.5 ml 
1 %(v/v) phenol red 37.5 μl 
H2O ad 50 ml, sterile filtrate 
25 % iodixanol 
 
10x PBS 5 ml 
1 M MgCl2 50 μl 
2.5 M KCl 50 μl 
Optiprep 20.9 ml 
1 %(v/v) phenol red 50 μl 
H2O ad 50 ml 
sterile filtrate 
40 % iodixanol 
 
10x PBS 5 ml 
1 M MgCl2 50 μl 
2.5 M KCl 50 μl 
5 M NaCl 10 ml 
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Optiprep 33.3 ml 
H2O ad 50 ml 
sterile filtrate 
60 % iodixanol 
 
1 M MgCl2 50 μl 
2.5 M KCl 50 μl 
Optiprep 50 ml 
1 %(v/v) phenol red 37.5 μl 
sterile filtrate 
 
 Purification of rAAVs via anion exchange chromatography 
For further virus purification, the ÄKTAprime plus chromatography system (GE Healthcare Life 
Sciences), HiTrap Q FF sepharose column (GE Healthcare Life Sciences), and PrimeView 
software (GE Healthcare Life Sciences) were used according to manufacturer's manual. The 
column was equilibrated with 25 ml of buffer A at 10 ml/min flow rate. The following manual 
run was selected with 1.0 ml/min flow rate and 1 ml fraction size. The virus phase was diluted 
1:1 with buffer A prior to injection with a 10 ml syringe to the superloop. Injection of the virus 
dilution from the superloop into the system was started and 1 ml fractions were collected in 1.5 
ml Eppendorf tubes. UV- and conductance curves were observed via the PrimeView software. 
When the conductance curve returned to base value, a switch to 100 % buffer B was performed 
at 10 ml/min flow rate and 0 ml fraction size to purge the sepharose column from remaining 
virus. It was then switched to sterile H2O to wash remaining salt from the column and system at 
10 ml/min flow rate. When the conductance curve reached zero, washing was continued for 20 
min. All 1 ml fractions within the plateau phase of the conductance curve were combined and 
stored at -20 °C until virus concentration as described in chapter 2.6.4. 
Buffer A: Tris 20 mM; NaCl 15 mM; H2O ad 1 l 
adjust pH to 8.5 and sterile filtrate 
Buffer B: NaCl 2.5 M; H2O ad 1 l 
adjust pH to 8.5 and sterile filtrate 
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 Concentration of rAAVs 
4 ml of the purified virus fraction was applied to an Amicon ultra-4 centrifugal filter unit with a 
100,000 molecular weight cutoff (Millipore) and centrifugation was done at 2000x g and 20 °C 
for 20 min (4000 rpm in a Beckman centrifuge using a JA-10 rotor). The flow-through was 
discarded and the residual virus fraction was applied to the Amicon filter. Centrifugation was 
continued until 500 μl remained in the filter unit. Washing was done with 1 ml 0.014 % 
Tween/PBS-MK by pipetting up and down five times. Centrifugation in 10 min steps was 
continued until 100 μl of concentrated virus suspension remained in the filter unit. It was then 
split into 10 μl aliquots and stored in 1.5 ml tubes with screw cap. Virus suspensions were stored 
at -80 °C until determination of virus titer and subretinal injection. 
 
 rAAV titer determination via quantitative real-time PCR 
To determine the genomic titer of the virus preparation by quantitative real-time PCR (QPCR), 
a standard curve was generated using a serial dilution of the WPRE fragment which was amplified 
from the pAAV2.1 vector with the following primers: 
WPRE for: AGTTCCGCCGTGGCAATAGG 
WPRE rev: CAAGGAGGAGAAAATGAAAGCC 
After amplification, the amplified fragment was precipitated with the aid of 3 M sodium acetate 
buffer pH 5.2 and ethanol. The DNA concentration was measured by determining the 
absorption at 260 nm with a NanodropTM 2000c spectrophotometer (Thermo Scientific). The 
concentration of the standard for 1010 genomic copies per 5 μl was calculated with the following 
equation: 
𝑐 (𝑝𝑔/𝜇𝑙) =
1010 ∗ 660 ∗ 1012
𝑝𝑔
𝑚𝑜𝑙
∗ 𝑠𝑖𝑧𝑒 𝑜𝑓 𝑊𝑃𝑅𝐸 𝑓𝑟𝑎𝑔𝑚𝑒𝑛𝑡
6.022 ∗
1023
𝑚𝑜𝑙
∗ µ𝑙
 
c = concentration of the standard for 1010 copies per 5 μl 
660 x 1012 pg/mol = mean molar mass of a base pair (deoxyribosyladenosine with 
deoxyribosylthymidine or deoxyribosylcytidine with deoxyribosylguanosine) 
6.022 x 1023 /mol = Avogadro constant 
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Afterwards, a tenfold serial dilution was generated in which the first dilution contained 1x1010 
copies/5 μl and the last dilution contained 1x 10 copies/5 μl. 5 μl of H2O was used for blank. 
Each dilution was amplified in two samples by qPCR using the Light Cycler LC480 (Roche). 
The SYBR green I (Roche) fluorescence intensity was analyzed for each cycle. The LightCycler 
software LC-Run (version 5.32, Roche) was used to generate a fluorescence curve and 
subsequently to calculate the crossing points (Cp) value which points out the cycle in which the 
fluorescence rises significantly above the background signal. The standard curve could then be 
formed from the logarithmized dilutions plotted against the Cp value. The purified and 
concentrated rAAV preparations were diluted 1:500 in H2O before two of each sample were 
amplified via qPCR. Fluorescence was measured as described above and a fluorescence curve was 
generated. The software then calculated the genomic titers by correlating the Cp values of the 
rAAV samples to the standard curve. 
Pipetting scheme for qPCR: 
WPRE primer for (10 μM)    1 μl 
WPRE primer rev (10 μM)    1 μl 
SYBR green I master mix   10 μl 
template     5 μl 
H2O          ad 20 μl 
 
qPCR conditions:  
Initial denaturation 95 °C  10 min 
Denaturation 95 °C 10 sec  
x 40 Annealing 60 °C 5 sec 
Elongation 72 °C 20 sec 
Final elongation 72 °C 5 min 
 
 Cell culture and plasmid transfection  
Human embryonic kidney (HEK) 293T cells were transfected with plasmid DNA containing the 
protein of interest. All cell culture work was performed under a laminar flow (Hera Safe, Thermo 
Scientific) under aseptic conditions.  
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The following plasmids were used in this study:  
pSub_U6_shRNAGucy_PKG_mcherry_SV40_WPRE 
pSub_U6_shRNAcGKII_PKG_mcherry_SV40_WPRE 
 
pCDNA3_CMV_cGKIImyc 
 
HEK293T cells were cultivated in DMEM + GlutaMAX medium (+ 4.5 g/l glu-cose, - pyruvate 
+ 10 % FBS) + 1 % penicillin/streptomycin (Biochrom) at 37 °C with 10 % CO2 in an 
incubator (Heraeus Cells, Thermo Scientific). Transient transfections of HEK293T cells were 
performed using the calcium phosphate technique.  
The calcium phosphate based transfection was performed by adding following solutions to a 15 
ml falcon tube (Sarstedt):  
 
DNA 20 μg  
2.5 M CaCl2 100 μl  
ddH2O ad 1 ml  
 
While vortexing this mixture, 1 ml 2 x BBS solution was added in a drop-wise manner. Then, the 
mixture was incubated for max. 5 min. at room temperature. This mixture was added drop-wise 
to the 50-70 % confluent cells and the cells were incubated at 37 °C with 5 % CO2 in an 
incubator (Hera Cell, Thermo Scientific). 24 h after transfection, the medium was replaced and 
the cells were incubated at 37 °C for 24 h with 10 % CO2 in an incubator (Hera Cell, Thermo 
Scientific).  
 
2 x BBS Solution  
BES 10.65g  
NaCl 16.35g  
Na2HPO4 0.21g  
H2O ad 950 ml  
adjust to pH 6.95 with NaOH and sterile filtrate using a 25mm syringe filter (VWR).  
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 shRNA validation  
HEK293T-cells were co-transfected with myc-tagged cGKII and shRNA. As a control HEK-cells 
were co-transfected with cGKII-myc and a scrambled sh-RNA. Two days after transfection HEK-
cells were harvested and protein (see section 2.23) was analysed by western blotting (see section 
2.24). HEK-cells transfected with cGKII shRNA display a significant reduction (49 %) of myc-
tagged cGKII. 
 
 Subretinal injection 
Two week old mice (P14) were intraperitoneally injected with ketamine (0.05 mg/g) and xylazine 
(0.01 mg/g). For older mice 0.1 mg/g ketamine and 0.02 mg/g xylazine was used. As soon as the 
mice were anesthetized Tropicamide eye drops were applied to the eyes for pupil dilation 
(Mydriadicum Stulln, Pharma Stulln GmbH, Stulln, Germany) and the mice were placed on a 
 A NanoFil 34-gauge beveled needle (World Precision Instruments) was placed 
into a glass syringe and loaded with the virus particles in PBS-MK. The different titer of charges 
of e.g. gene of interest and control were fitted by according dilution titer-matched rAAV copies. 
Using a stereomicroscope the eye fundus was visible and at a roughly 60 ° angle the eye was 
penetrated by the needle until it was visible beneath the retina. After slow injection of 1 μl of 
virus suspension, the formation of a clear subretinal bleb confirmed the correct application into 
Figure 2-3: shRNA validation. HEK293T-cells were 
cotransfected with cGKII-myc and either cGKII-shRNA (cGKII-
sh) or scrambled shRNA (ctrl-sh) as a control. By western blotting 
myc-tagged  cGKII was detected and efficiency of the shRNA was 
determined by quantification (b) Summary data are mean ± SEM. 
-test)  
 
 
Materials and Methods 
51 
the subretinal space. For verification of subretinal application an OCT- scanning laser 
ophthalmoscopy (Spectralis, Heidelberg Eye Instruments) was used. 
The needle was carefully withdrawn and the injected eye was treated with gentamicin 5 mg/g and 
dexamethasone 0.3 mg/g eye salve. The anaesthetized mouse was placed under a heat lamp and 
was kept under supervision until it awakened from the narcosis. Minimum 10 days were required 
for sufficient protein expression in the retina. Two weeks post injection, retinas were analyzed for 
the fluorescence using scanning laser ophthalmoscopy (Spectralis, Heidelberg Eye Instruments). 
 
 Ophthalmological examinations  
For ophthalmological examinations, adult mice received intraperitoneal injections of ketamine 
(0.1 mg/g) and xylazine (0.02 mg/g). Before the scanning procedure, Tropicamide eye drops were 
applied to the mice eyes for pupil dilation (Mydriadicum Stulln, Pharma Stulln GmbH, Stulln, 
Germany). Subsequently, hydroxylpropyl methylcellulose (Methocel 2 %; OmniVision, 
Puchheim, Germany) was applied to keep the eyes moist. The examination was performed with 
an adapted Spectralis HRA + OCT system from Heidelberg Engineering (Dossenheim, 
Germany) in combination with optic lenses described previously (Schon et al., 2012). The system 
allowed for imaging of the eye fundus by confocal laser scanning ophthalmoscopy (cSLO) and 
examination of the retinal morphology by optical coherence tomography (OCT). OCT scans 
were conducted with a 12° circular scan mode centered at the optic nerve head. This procedure 
Figure 2-4 Ophthalmological examination. Optical coherence 
tomography (OCT) and confocal laser scanning ophthalmoscopy 
(cSLO) was performed with a Spectralis HRA and OCT system 
from Heidelberg Engineering (Dossenheim, Germany). 
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enabled measurements of the photoreceptor layer thickness at a comparable distance from the 
optic nerve head and allowed for comparison of values in longitudinal examinations of the same 
eye and between individuals. In detail, photoreceptor layer thickness was measured between the 
clearly visible outer plexiform layer and the border of neuronal retina and the RPE. The 
photoreceptor layer thickness is equivalent to the term photoreceptor plus occasionally used in 
other studies for quantification of OCT data. For statistical analysis, the mean photoreceptor 
layer thickness was calculated from single values measured in the dorsal, temporal, nasal and 
ventral region around the optic nerve. cSLO images of the eye fundus were obtained using the 
infrared laser (820 nm) and the scanner set to a 30° field of view at high resolution mode. 
 
 SDS-polyacrylamide electrophoresis (SDS-PAGE) 
A gradient SDS-polyacrylamide gel (SDS-gel) was used to separate isolated proteins according to 
their molecular weight. 6-12 % separation gels were prepared using the Mini Protean 3 gel system 
(BioRad). PageRuler Prestained Protein Ladder (Thermo Scientific) was loaded together with the 
protein samples to determine the protein sizes. Electrophoresis was run at 60 mA until the 
protein ladder bands were clearly separated. 
10x electrophoresis buffer 
Tris   30 g 
glycin   144 g 
SDS   10 g 
H2O ad 1 l 
 
4x Tris-HCl/SDS pH 6.8 buffer 
Tris-HCl  0.5 M 
SDS   0.4 % 
adjust pH to 6.8 
 
4x Tris-HCl/SDS pH 8.8 buffer 
Tris-HCl  1.5 M 
SDS   0.4 % 
adjust pH to 8.8 
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Stacking gel (for 2 gels) 
30 % acrylamide/bis-acrylamide  1 ml 
4x Tris-HCl/SDS pH 6.8 buffer  1.9 ml 
H2O      4.6 ml 
APS      37.5 μl 
TEMED     7.5 μl 
 
Separation gel (for 2 gels) 
6 % gel  12 % gel 
30 % acrylamide/bis-acrylamide  2.3 ml   4.6 ml 
4x Tris-HCl/SDS pH 8.8 buffer  2.8 ml   2.8 ml 
H2O      6.2 ml   3.9 ml 
APS      22.5 μl  22.5 μl 
TEMED     7.5 μl   7.5 μl 
 
Pipet 4 ml 6 % gel solution and then 5 ml of 12 % gel solution into a 10 ml pipette. Gently mix 
by aspiring one air bubble before pouring the gradient gel solution into the gel system. 
 
 Whole cell protein lysates  
The tissue was rinsed twice in 0.1 M PB buffer and then lysed in 500 µl RIPA lysis buffer (5 M 
NaCl, 0.5 M EDTA (pH 8.0), 1 M Tris, pH 8.0, NP-40 (IGEPAL CA-630), 10% sodium 
deoxycholate, 10% SDS, add 100ml dH2O) containing protease inhibitor and phosphatase 
inhibitor (Mass Spectrometry Safe Protease and Phosphatase Inhibitor Cocktail, Sigma). The 
tissue was homogenized by a mortar and pestle. Susequently samples were centrifuged with 
maximum rmp and supernatant was retained. Samples were either further processed or stored at  
80 °C for long-term storage.  
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 Western blotting 
Western blotting was performed at 90 V for 1-2 hours in a mini trans-blot cell (BioRad) 
according to standard procedure. After the protein transfer to the PVDF membrane, the latter 
was shortly blocked in 5 % milk powder for 10 min at room temperature with shaking. Then, the 
incubation of the membrane with the appropriate primary antibody was performed. The optimal 
incubation time and the optimal antibody concentration were determined empirically. Hereafter, 
the membrane was washed three times in TBST for 5 min followed by a 1-2 h incubation with 
the secondary antibody at room temperature with rotation. The membrane was washed 3-4 times 
with TBST for 5 min and once in ddH2O. After the incubation with the western blotting 
s protocol the chemiluminescence was 
detected using the Chemidoc MP Imaging system (BioRad) and ImageLab software. The optimal 
exposure time was determined empirically. 
 
Transfer buffer 
Tris   3 g 
glycin   14.4 g 
H2O ad 1 l 
 
10x TBS 
Tris   12.1 g 
NaCl   80.2 g 
H2O ad 1 l 
 
TBST 
10x TBS  100 ml 
Tween 20  1 ml 
H2O ad 1 l 
 
Blocking solution 
TBST   15 ml 
milk powder  0.75 g 
H2O ad 1 l 
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Table 2.8 Antibodies used for western blotting 
Antibody company Dilution IHC 
mouse anti-myc 
Purchased from Cell 
Signaling 
1:2000 
mouse anti-alpha-tubulin Dianova, Hamburg 1:2000 
goat anti-Atr Santa Cruz 1:200 
mouse  anti-NPM1 abcam 1:100 
anti-mouse HRP Santa Cruz 1:2000 
anti-goat HRP Santa Cruz 1:2000 
 
 Co-immunoprecipitation (Co-IP)  
Immunoprecipitation was performed using Protein G Dynabeads (Invitrogen) according to 
instructions. Briefly, protein extracts were prepared without the use of detergents 
100 μl beads were added in a 1.5 ml Eppendorf tube together with 1-2 µg primary antibody. 
Next, the volume was adjusted to 500 μl using 0.1 M PBS and incubated for 30 min at 4 °C 
under rotation. Tubes were placed on a magnet rack for precipitation and the supernatant was 
discarded. The beads were washed twice with 300 μl PBS solution. Subsequently, 500 μg protein 
lysate was added to the beads and incubated for 30-60 min at 4 °C under rotation. The 
supernatant was discarded and the beads were washed 3 times with 300 μl PBS solution. After the 
last wash, the suspension was transferred into fresh 1.5 mL Eppendorf tubes and the supernatant 
was removed completely. Beads were resuspended in 6 x Lämmli buffer (with or without DTT, 
depending on the application) and incubated at 70°C for 15 min. Finally, the supernatant was 
loaded on the appropriate SDS PAGE gel. 
osslinked to the beads by means of 
irreversible, non-cleavable crosslinker BS3 (Thermo Scientific). For this purpose, after the 
coupling of the antibody to the beads, BS3 was added to the reaction in a final concentration of 5 
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mM. Then, the suspension was incubated for 30 min at room temperature and was quenched 
subsequently by adding Tris-HCl pH 7.5 (final concentration 50 mM) and incubating the 
reaction for 15 min at room temperature. Then, protein lysate was added and the reaction was 
processed as described above. 
 
 Retina dissociation 
RG-eGFP positive mice or RG-eGFP x Cnga3 
KO mice were euthanized with Isofloran and 
then sacrificed. Eyes were protruded out of the 
orbit (exophthalmus) and fixed with curved 
forceps. With a sharp blade, the cornea was cut 
and by pulling the forceps the retina was 
smoothly extracted from the eye. After rinsing in 
cold PB (0.1M) and removing the lense as well as 
remaining RPE the tissue was transferred into a 
1.5 ml reaction tube containing 250µl papain 
solution (provided by the papain dissociation 
kit). Retinas were incubated in the papain 
solution for 20-30 min in a shaker (400 rpm) at 
37 °C. After papain incubation the papain 
solution containing the partially digested retina 
were transferred into an EBBS-solution 
containing 60 μl of DNase I (10 mg/ml) + 60 μl of ovomucoid solution (provided by the kit). 
Using a fire polished pipette, mechanical dissociation was performed (10x up and down). Single 
cell suspension was pipetted gently on top of 1 ml of ovomucoid solution, to generate two layers. 
Suspension was centrifuged for 5 min at 300 g (approximately 1,300 rpm). The supernatant was 
discarded and cells were resuspended in 500 μl of cell medium for sorting by Fluorescence-
activated cell sorting (FACS).  
 
Figure 2-5: Fluorescence-activated cell 
sorting (FACS). Dissociated retina with eGFP-
expressing cones have been sorted by FACS to 
obtain pure cone-lysates. 
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 Fluorescence-activated cell sorting (FACS) 
Cells were analyzed with a FACS Aria II instrument (Becton Dickinson) and data analysis was 
performed using FlowJo version 7.2.5. eGFP positive cells were sorted into EBBS medium 
(provided by the papain dissociation kit) and cell pellets were stored at -80°C for protein 
purification and mass spectrometry.  
FACS-sorting was performed with the help of Dr. Daniela Meilinger (Group of Prof Heinrich 
Leonhardt, Faculty of Biology at the LMU, Munich) 
 
 Phosho-enrichment of Proteins 
50 μl (1 mg) of MagReSyn® Ti-IMAC were washed twice in 200 μl of 70 % ethanol on a 
magnetic separator with gentle agitation (e.g. vortex mixing) for 5 min. Then microparticles were 
washed in 100 μl of 1 % NH4OH on a magnetic separator with gentle agitation (e.g. vortex 
mixing) for 10 min. Last particles were equilibrated thrice in 50 μl loading buffer (1M glycolic 
acid in 80 % ACN, 5 % TFA) for 60 s. The loading buffer was removed and microparticles were 
ready for phospho-enrichment. 
Protein digest was adjusted (containing ~455 μg total protein) with one equivalent volume of 
loading buffer (100 µl) and added to the equilibrated MagReSyn® Ti-IMAC microparticle pellet. 
Microparticles were resuspended in the peptide sample by vortexing or pipette aspiration. After 
incubation for 20 min at room temperature with end-over-top mixing, the tubes were placed on a 
magnetic separator and microparticles were allowed to clear. Coupling supernatant was remove 
and discarded. Unbound sample was removed by washing with 100 μl of loading buffer for 30 s 
with gentle agitation. The tube was placed on a magnetic separator and the supernatant was 
removed and discarded. Non-specifically bound peptides were removed by resuspending the 
microparticles in 100 μl wash buffer (aqueous solution of 80 % ACN and 1 % TFA) for 2 min 
with gentle agitation. The supernatant was removed and discarded on a magnetic separator. 
Washing was repeated with 100 µl of wash buffer and again discarded on a magnetic separator. 
Bound phosphopeptides were then eluted from microparticles by adding 80 μl elution buffer 
(1 % NH4OH) for 15 min under constant gentle agitation. Elution was repeated twice to obtain 
a final elution volume of 240 μl. On a magnetic separator the eluate containing the 
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phosphopeptides was removed and transferred to a new tube. 60 μl of 10 % Formic Acid was 
added to the 240 μl eluate to acidify the solution. Samples were analysed the by mass 
spectrometry. 
 
 Mass-spectrometry 
Whole cell protein lysates were incubated with 1 µL Benzonase for 1 h at 0 °C. Then, 250 µL of 
MS-grade water was added and 4 retinas (2 animals) were pooled together. To precipitate the 
proteins, 7 mL of ice-cold acetone was added to each sample and they were incubated at -20 °C 
overnight. After centrifugation at 10000g for 10 minutes, the supernatant was removed and the 
pellet was washed two times with 1 mL of 80% acetone(aq) each. 
To the resulting pellets 2 mL of digestion-buffer (50 mM TEAB, 1 mM MgCl2 in MS-grade 
water) and 2 mL of MS-grade water were added and the samples were sonicated (5 cycles @ 50% 
power output, 5 min) on ice to resuspend the samples. The protein concentration of the samples 
was determined by conducting a Bradford assay. 
For full proteome analysis, from each triplicate of the samples 2.25 µg of protein content were 
diluted with digestion-buffer to give a total volume of 100 µL. The proteins were reduced with 
TCEP(aq) (5 µL, 1M) for 45 min at 60 °C and thereafter neutralized with TEAB(aq) (30 µL, 1M) 
and alkylated with iodoacetamide(aq) (6 µL, 1M) for 30 min at room temperature in the dark. 
Finally, trypsin (2 µL, 0.1 µg/µL in 50 mM AcOH(aq)) was added and the samples were incubated 
at 37 °C and 350 rpm with interval mixing on a thermomixer overnight. 
For phosphoenrichment samples, a volume equivalent of 445 µg protein content was taken for 
the knock-out, the wild type and the IIA-samples. Since not enough protein could be recovered 
from the biological replicates of IA-samples, only a volume containing 283.5 µg protein amount 
was used. For digestion, samples were processed in the same way as for the full-proteome analysis 
with the following amounts: TCEP(aq) (1M) was added to a final concentration of 41.8 mM, 
255 µL of TEAB(aq) (1M) were added to neutralize the solution, iodoacetamide(aq) (1M) was added 
to a final concentration of 41.1 mM and 210 µL of TEAB(aq) (1M) were added to adjust the pH-
value for digestion. Finally, 5 µg trypsin were added per sample (3 µg in case of the IA-triplicate 
samples). 
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After digestion, peptides were desalted by stage-tip purification (SDB-RPS material, see Kulak et 
al., 2014) and concentrated to dryness on a speed-vac. Full proteome samples were solved in 12 
µL MS-solvent (MS-grade water, 0.1% formic acid, 2% MeCN) each and analysed by mass 
spectrometry. 
The phosphoenrichment samples were processed as described in 2.28. After elution, 
phosphopetide-containing samples were acidified with FA(aq) and desalted by stage-tip 
purification (SDB-RPS material, see Kulak et al., 2014) and concentrated to dryness on a speed-
vac. The phosphopetide-samples were solved in 12 µL MS-solvent and analysed by mass 
spectrometry. 
Mass spectrometry and MaxQuant Analysis was performed by Andrea Künzel and Michael 
Stadlmeier (Carell group, LMU Munich).  
 
 Statistics 
All values are given as mean ± standard error of the mean (S.E.M) or mean ± standard deviation 
(SD) and n is the number of experiments. An unpaired Student's t-test was per-formed for the 
-
test was applied to analyse significance of contingency tables.   
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 Results 
 Transcriptional changes in the retina of Cnga3 KO mice 
Gene expression changes in the retina of Cnga3 KO mice, were investigated by a Microarray 
approach. The overall up- and down-regulation of gene-transcripts is visualized in a heatmap 
shown in Figure 3.1A. At four weeks after birth (PW4) 561 genes have a changed expression-
pattern while at eight weeks after birth (PW8) only 257 genes are detected to be misregulated. 
Taking a closer look at the transcriptional changes, it is apparent that a considerably higher 
number of genes are down-regulated at PW4 (498) compared to genes being down-regulated at 
PW8 (129). The number of genes up-regulated on the other hand is twice as much at PW8 (128) 
compared to PW4 (63). Gene Ontology analysis uncovered the gene groups being misregulated 
in the Cnga3 KO mouse model showing a high representation of enzymes and a relatively high 
number of transcription factors (Fig3.1B). By pathway analysis with the computer program 
Ingenuity IPA the significance of regulated genes can be evaluated in the context of biological 
systems. The analysis divides the data into cellular functions termed as biological processes and 
metabolic processes termed as canonical pathways. Over represented pathways, associated to the 
dis-regulated genes, can then be detected. 
profoundly 
d.  
 
 cGMP accumulation in cones of Cnga3 KO mice 
In the outer nuclear layer (ONL) of Cnga3 KO mice an increase of cGMP could be detected by 
immunohistochemistry. cGMP could be detected by an antibody raised against a cGMP-
formaldehyde-thyroglobulin conjugate (de Vente et al., 1987, Ikawa et al., 2003)). 
As displayed in Figure 3.2, Cnga3 KO mice show an enhanced level of the second messenger 
cGMP compared to age-matched wild type mice with the same background. Most importantly 
this increase is cone specific and present throughout the degeneration process.   
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Fig3.1: Gene expression analysis during cone photoreceptor degenera tion. (A) A heat map visualizes the up- 
and dowregulation of genes in Cnga3 KO compared to wild type mice at four and eight weeks after birth 
(PW4/PW8). While 561 genes are detected to be deregulated at PW4 only 257 genes show a different expression at 
PW8 (B) Gene ontology analysis on genes being deregulated during the degeneration of Cnga3 KO mice reveals the 
function of the gene groups being deregulated. (C) By pathway analysis, biological processes and canonical 
pathways can be determined which are associated to a significant number of dysregulated genes. The p-value shows 
if this association is due to random chance or significant. (All displayed Pathways have a p-value <=0.05) 
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The accumulation could be detected several days before eye opening (P6) and before full 
maturation of the retina. Interestingly, cGMP accumulation persisted in the few residual 
surviving cones in the dorsal part of the twelve-month-old Cnga3 KO mouse retina (PM12, 
Fig3.2 C). The earliest time point of detection was four days after birth (P4, Figure 3.2A). At this 
time point only a few cones show a faint and spotty cGMP-positive staining. At P6 however the 
cGMP signal further broadened and is present in all cones of the mouse retina (Figure 3.2 A). 
Taken together the data shows an accumulation of cGMP at remarkably early time points until 
very late stages of degeneration in the adult mouse (Fig 3.1).  
Fig: 3.2: cGMP accumulation in cones of Cnga3 KO mice. At postnatal day four (P4) a week signal for 
cGMP is detected in the retina of Cnga3 KO mice. This signal increased at P6 (A; scale bar marks 10 µm). 
Throughout maturation (P7-P21) an accumulation of cGMP is present in cones (B, scale bar marks 25 µm) and 
sustained throughout the degeneration process (C, scale bar marks 25 µm). Even at very late stages of the 
degeneration process (PM12) when only a few cones are residual, cGMP accumulation is still detected (C). This 
accumulation can be detected in dorsal as well as ventral cones at all given time points as seen in D (PW4). 
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 Knock-down of guanylyl cyclase during degeneration 
Guanylate cyclase 2E (encoded by Gucy2e) is the only known cGMP-producing enzyme present 
in cones (Sokal et al., 2003, Takemoto et al., 2009, Yang et al., 1999). To test if the observed 
cGMP accumulation (Figure 3.2) is critically involved in photoreceptor cell death or just 
represents a bystander effect of the degeneration, Gucy2e in Cnga3 KO retina was down-regulated 
using specific shRNA.  
For the purpose of in-vivo cone tracing Cnga3 KO mice were first cross-bred with mice 
expressing eGFP under the control of the cone specific human red/green opsin (RG)-promoter 
(Ikawa et al., 2003). An adeno associated virus (AAV)-vector expressing a Gucy2e-specific shRNA 
and the fluorescent marker protein mCherry was then delivered into the subretinal space of 
RgeGFP x A3ko-mice (Figure 3.3). To interfere with Gucy2e expression before the peak of 
apoptosis at PW3 and before the degeneration sets in, the Gucy2e-specific shRNA was applied 
right after eye opening at P14. Only one eye (OD, right) was injected, while the second eye (OS, 
left) served as a control to monitor the degeneration process in direct comparison. After two 
weeks of recovery the density of eGFP-positive cone photoreceptors and the range of shRNA-
expression could be determined by measuring the fluorescence of the reporter genes (eGFP and 
mCherry) by in vivo confocal laser scanning ophthalmoscopy (cSLO, Heidelberg spectralis) 
(Figure 3.4 A-D).  
 
Figure 3.3: Subretinal 
application of a shRNA 
directed against the cGMP-
producing guanylyl cyclase. 
The sh-RNA was cloned into a 
recombinant Adeno associated 
virus (rAAV)-vector 
downstream of an U6-
promoter with mcherry as a 
report gene. After AAV-
production the virus was 
injected subretinally in close 
proximity to the photo-
receptors of Cnga3 ko and wild 
type mice. 
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Figure 3.4: Prolonged survival of cone photoreceptors in 
Cnga3 KO mice after down regulation of cGMP-
production during degeneration process. A shRNA-directed 
against the Guanylyl cyclase 2e, expressed with mCherry as a 
report gene was applied to the retina of Cnga3 KO mice. This 
knock down delayed the degeneration of eGFP-positive cones 
in the ventral part of a treated compared to an untreated retina 
11 weeks after injection at PM3 (A). Quantification of eGFP-
positive cones in the treated (mcherry-positive) area displays a 
significant decline of cone degeneration (B). 
-test)  
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Cone survival was then ascertained by counting the number of eGFP-positive cells in the 
designated area. 
Measurements of eGFP and mcherry fluorescence were repeated at an interval of one week. 
Already 11 weeks after the injection (at 13 weeks of age/PM3) a significant difference of the 
number of cones could be detected between the treated and untreated eye of Cnga3 KO mice 
(Fig3.4 E). Cones were quantified in an area of ~6020 µm² of the retina of treated and untreated 
eye. 
 
 cGMP dependent kinases (cGKs) in the retina 
To further understand how a dysregulation of cGMP-levels can lead to cell-death, it was most 
essential to investigate the signalling downstream of cGMP in the retina. Alongside the CNG 
channel other targets known to be regulated by cGMP are the cGMP-dependent kinases (cGK) I 
and II. To clarify whether these alternative cGMP effectors influence the cone degeneration in 
the disease of Achromatopsia, the expression level and pattern of cGKI (Prkg1) as well as cGKII 
(Prkg2) was further examined. qRT-PCR measurements showed that both kinases are present in 
the adult mouse retina. Figure 3.5 shows the expression of these cGMP-targets at three different 
postnatal developmental stages. While cGKI is relatively low expressed before eye opening (P6), 
the expression level gradually increases during retinal maturation. There was no apparent 
difference in cGKI mRNA levels between wt and Cnga3 ko retina. cGKII expression was rather 
constant with during this period of time with only a minor increase at two weeks after birth. At 
p6 cGKII mRNA levels were similar in wt and Cnga3 ko retina. However, around eye opening 
(p14) there was a transient and significant increase in the expression level of cGKII in the Cnga3 
KO retina when compared to the wt (Fig 3.5).  
Sorting retina lysates by a fluorescence-activated cell sorter (FACS) resulted in pure rods or cones. 
RNA extracted from these pure fractions were then used for expression analysis of cGKI and 
cGKII by qRT-PCR. Both kinases show an enrichment in cones compared to rod photoreceptors 
(Figure3.5CB). The localisation of cGKI in the retina was further determined by 
immunohistochemistry and showed that cGKI is mainly expressed in Müller glia cells (Figure 3.5 
C). A suitable cGKII-specific antibody was not available. 
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 Overexpression of cGK in wild type mice 
Based on the finding that cGMP accumulates in diseased photoreceptors, it is likely that the 
respective effectors of cGMP are more active. To evaluate whether increased cGK-activity can 
influence the photoreceptor viability, AAV vectors expressing a constitutively active cGK variant 
were delivered into the subretinal space of wild type mice. 
cGKs are known to be regulated by an N-terminal regulatory domain which changes the 
conformation upon binding of cGMP (see Figure1.9). Without its regulatory domain cGK is 
independent of an activation by cGMP and can phosphorylate its targets in the absence of the 
Figure 3.5: Expression pattern of the cGMP dependent kinases (cGKs) in the retina of Cnga3 KO mice: 
Expression of Prkg1(cGKI) gradually increases during development from postnatal day 6 (P6) until P28 with 
no apparent difference between Cnga3 ko and wildtype (wt) mice. Prkg2 (cGKII) shows more constant 
expression levels in the wt. However, in the Cnga3 ko cGKII shows a transient and significant increase at P14. 
(A). Both, cGKI and cGKII, mRNA is enriched in cone photoreceptors compared to rod photoreceptors (B). 
Immunohistochemical staining of four weeks old wt and cGKIko mouse retinal cross-sections using a cGKI-
specific antibody. cGKI immunosignal (red) is found in all retinal layers with a strong signal in Müller glia cells 
(C, scale bar marks 25 µm ). * -test). 
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ligand, it is so called constitutively active (Ruth et al., 1997, Boerth and Lincoln, 
1994, Deguchi et al., 2004). The regulatory domain of cGKI lacking the N-terminal regulatory 
domain part was cloned with a Rhodopsin-promoter for rod photoreceptor-specific expression 
and a 2A-eGFP cassette into an AAV vector plasmid (Figure 3.6 and section 2.16 and Figure 2.1, 
Materials and Methods). From this vector CAcGK was coexpressed with the reporter gene eGFP 
- -region, ensuring equimolar levels of both genes (Robertson et 
al., 1985, Donnelly et al., 2001). A vector expressing solely eGFP under the same promoter was 
used in the control experiment (Figure3.6). Both constructs were packed as AAV8 (Y733F 
mutant) particles and delivered into the retina by subretinal injection. After one week of recovery 
the fundus and thickness of the retina of these mice were monitored each week. eGFP 
fluorescence, marking the treated region of the injected retina, could be determined by confocal 
laser scanning ophthalmoscopy (cSLO)-imaging (not shown). Expression of eGFP alone had no 
effect on the outer nuclear layer (ONL) thickness. However, treatment with the constitutive 
active cGK (cA-cGK)-expressing vector resulted in a continuous time-dependent decrease in the 
outer nuclear layer (ONL) thickness over a time-frame of five weeks (Figure 3.7A). After five 
weeks a tremendous effect could be observed and the photoreceptor layer of the cA-cGK-injected 
eye was completely lost (Figure 3.7 B). Quantification of this difference is highly significant 
(Figure 3.7 C).  
 
Figure 3.6: Expression of a 
constitutively active cGMP-
dependent kinase (cGK) in 
mouse photoreceptors. The 
catalytic domain of the cGMP-
dependent kinase (cAcGKI) 
was cloned behind the rod-
specific rhodopsin-promoter 
with eGFP as a reporter gene 
for Adeno-associated-virus 
(AAV) production to achieve 
cell-specific gene-delivery. 
eGFP cloned behind the 
rhodopsin-promoter served as a 
control. 
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 Knockout of cGK during degeneration delays cone degeneration in 
Cnga3 KO mice 
Providing that a high activity of cGMP-dependent kinase can induce cell death in 
photoreceptors, the next step was to determine whether the activity of this kinase is involved in 
the cell death of photoreceptors in Achromatopsia. To assess the influence cGMP dependent 
kinases might have on the degeneration process, mice carrying a Cnga3 disruption (A3 KO mice) 
were crossbred with either cGKI KO or cGKII KO mice. Since a complete knock-out of cGKI in 
mice leads to premature lethality at approximately 6 weeks due to smooth muscle dysfunction. 
Therefore, cGKI mice were used with a smooth muscle (SM)-specific knock-in (ki) of cGKI to 
rescue this phenotype while all other cell types lack cGKI expression (Weber et al., 2007). The 
cGKI KO / SM-  mice are hereafter abreviated as cGKI KO mice.  
 
Figure 3.7: High activity of cGMP-dependent kinase (cGK) leads to photoreceptor death in 
wild type mice. Constitutively active cGK (cA-cGK) was expressed in wildtype retina and thickness 
of the outer nuclear layer (ONL) was monitored in vivo during a five weeks post injection observation 
period. Optical coherence tomography (OCT)-analysis showed a progressive loss of the ONL in 
animals treated with cA-cGK, while eGFP treated control animals showed a stable retina thickness 
over the same time frame (A). Panel B shows the retina thickness of treated Quantification of the 
ONL thickness showed a significant difference between cAcGKI-treated retina compared to either 
untreated or eGFP-treated retina (C). N=3 -test) 
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Figure 3.8: Cone survival in Cnga3 KO mice upon knock out of cGMP dependent kinases (cGKs). (A/B) 3 and 
5 months after birth (PM3/5) cGKII/Cnga3 dko mice show a higher density of cones in the ventral and dorsal part of 
the retina compared to Cnga3 ko mice. A quantification (C) shows that the difference in cone survival is significant at 
PM3 and PM5. A knock out of cGKI had no influence of cone survival (D) but interestingly knocking out both 
kinases in the Cnga3 KO model has an even stronger effect on the viability of cones.  N>=3, * p < 0.05 ** p< 0.01 *** 
-test); Scale bar marks 25 µm.  
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The generated cGKI/Cnga3 and cGKII/Cnga3 double KO (DKO) mice were born in normal 
Mendelian ratio and had a life span similar to the single knockout mice. Next, these mouse lines 
were used for comparative quantification of the number of surviving cones in the dorsal and 
ventral part of the retina. Retinal tissue was collected at the age of PW4, right after the peak of 
photoreceptor death, but also at PM3 and PM5 mice and cone survival was evaluated.  
Loss of cGKI showed no positive effect on the cone survival in Cnga3 KO mice. A significant 
difference could be detected at PM3 and PM5 between cGKII/Cnga3 DKO and Cnga3 KO 
retina. cGKI/cGKII/Cnga3 triple knock out (tko) SM ki mice were also generated and showed an 
even more pronounced rescue of cones at PM3 (Figure 3.8).  
In order to further support the finding that less photoreceptors are dying in cGKII/Cnga3 DKO 
mice, a TUNEL assay was performed. By TUNEL assay DNA fragmentation, a programmed 
hallmark of cell death (Negoescu et al., 1998, Gavrieli et al., 1992), is visualized by incorporation 
of fluorescent dUTPs at the -OH ends of DNA fragments. At PW4 the retina of cGKII/Cnga3 
DKO mice displayed a significantly lower number of cells undergoing cell death compared to 
Cnga3 KO mice (Figure 3.9).  
  
Fig 3.9 Reduced photoreceptor cell death in Cnga3/cGKII dko mice. (A) TUNEL  
staining display a decrease of cells undergoing cell death in cGKII/Cnga3 DKO mice 
compared to Cnga3 KO mice four weeks after birth (PW4)(B) Quantification of TUNEL-
positive cells  shows the decrease of cell-death is significant. N=3, -
test); Scale bar marks 25 µm 
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Figure 3.8: Delayed degeneration in Cnga3 
KO mice after down regulation of cGMP-
dependent kinase II (cGKII). An AAV 
vector expressing a specific shRNA directed 
against the cGKII with mCherry as a report 
gene was applied to the retina of Cnga3 KO 
mice (C/D). This knock down delayed the 
degeneration of eGFP-positive cones in the 
ventral part of a treated (B) compared to an 
untreated (A) retina 3 months after injection. 
Quantification of eGFP-positive cones in the 
treated (mcherry-positive) area displays a 
significant decline of cone degeneration (E). 
N=3,  
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 Knock-down of cGK II 
To evaluate possible therapeutic options and to potentially increase the window of opportunity 
for gene replacement therapy, a AAV-vector was generated expressing a cGKII-specific shRNA 
under control of an U6-promoter and used for packaging AAV8 (Y733F mutant) vector particles 
for delivery in vivo experiments. After subretinal injections in Cnga3 KO mice at the age of two 
weeks, the shRNA-expression was monitored indirectly by imaging the mCherry reporter gene 
encoded by the same AAV vector genome using SLO. The cone density was also monitored by 
SLO-imaging each week. Again Cnga3 KO mice were used with eGFP tagged cones (Cnga3 KO x 
RgeGFP-mice) for in vivo-detection. At about 10 weeks after delivery (PM3) quantification of 
surviving cones in the shRNA-treated area of Cnga3 KO mice revealed a significantly higher cone 
density compared to the untreated eye (Fig 3.10). 
 
 cGKII signalling in the retina 
Various substrates of cGKI and cGKII have already been identified but for the central nervous 
system (CNS) and the retina in particular their targets are still largely unknown. In order to 
further understand the degeneration and the role of cGMP in the process it is indispensable to 
determine which proteins get phosphorylated by the cGMP regulated kinases.  
 
 Mass spectrometry based analysis of proteins expressed in cone photoreceptors.   
A mass spectrometry based approach was chosen to identify proteins enriched in degenerating 
Cnga3 KO cone photoreceptors. In order to obtain pure cone preparations, RgeGFP-expressing 
wildtype and Cnga3 KO mouse retinas were dissociated and single-cell solutions were used for 
fluorescence-activated cell sorting (FACS). Protein-lysates of the retained eGFP-positive cones 
were then analysed by label free quantification (LFQ) liquid chromatography coupled to mass-
spectrometry (LC-MS). Evaluation with the Perseus software (version 1.5.0.9) identified the 
protein Nucleophosmin (Npm1) enriched in Cnga3 KO cones with a highly significant ratio 
compared to wildtype cones as visualized in the volcano plot of Figure 3.11 A. 
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Npm1 also known as nucleolar phosphoprotein, B23, numatrin or NO38, is a protein involved 
in a variety of cellular functions ranging from ribosome biogenesis, cell cycle regulation, 
centrosome duplication, genomic stability, apoptosis and protein folding (Pfister and D'Mello, 
Fig 3.11 Mass spectrometry based analysis of proteins expressed in cone photoreceptors. (A) Volcano 
plot shows the ratios of proteins between FAC-sorted wildtype cones and Cnga3 KO cones as a function of 
statistical significance (Student t-test -log p value). Proteins with no detectable signal in one of the subsets 
were assigned a value of zero. Nucleophosmin (Npm1) was detected to be enriched in Cnga3 KO cones. (B) 
On protein level of whole retina lysates the increased level of Npm1 could be verified. (C) mRNA expression 
analysis by QPCR show a significant increase of Npm1 expression at PM3 (N=3, -test). 
(D) Immunohistochemistry verifies an increase of Npm1 in the outer nuclear layer of Cnga3 KO mice. The 
stainings with the cone marker glypho further show an enrichment of Npm1 in cones compared to rods in 
both genotypes. (scale bar marks 5µm).  
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2015). Npm1 shuttles between cytoplasm and nucleus but is mainly located in the nucleolus 
(Szebeni et al., 1995, Borer et al., 1989)- 
  
Fig 3.12 Phospho-proteomics of retina with different genetic modifications. (A) For phospho-enrichment 
Ti
4+
-magnetic beads were used. Obtained proteins were identified by label free quantification (LFQ) mass 
spectrometry. (B-D) Volcano plots show the ratios of detected phosphorylation sited of the given proteins between 
wildtype mice and Cnga3 KO mice or Cnga3 KO and cGKII/Cnga3 DKO mice or cGKII/Cnga3 DKO and 
cGKI/Cnga3 DKO mice as a function of statistical significance (Student t-test p value  (E) Venn 
Diagramm visualizes overlaps of enriched proteins identified in the volcano plots of B-D. 
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In the wildtype retina Npm1 is mainly detected in nuclei of the ganglion cell layer and inner 
nuclear layer but is also present in the outer nuclear layer (Fig 3.11 D). In the ONL the staining 
clearly shows an enrichment in cone nuclei, while in rods NPM1 is rather detected in the 
cytoplasm (Figure 3.11 D). Immunohistochemistry and western blot both indicate a slight 
increase of Npm1 in Cnga3 KO retina (Figure 3.11 B/D). qRT-PCR gene expression analysis 
also revealed higher Npm1 transcript levels in the Cnga3 KO retina, however, the increase does 
not reach significance until three months after birth (Fig3.11 C).  
Fig 3.13 Activation of Atr. (A) By immunohistochemistry the distribution of the serine/threonine-kinase 
ATR can be detected in the retina. An antibody specifically detecting proteins carrying the recognition 
sequence of Atr displays the localisation of possible substrates. (B) Western blotting shows no difference in 
the protein level of Atr (N=3, PW4) (C) H2AX gets phosphorylated by ATR (γ-H2AX) and is a marker for 
DNA-damage High levels of γ-H2AX can be detected in several Cnga3 KO cone nuclei but not in cones  of 
cGKII/Cnga3 DKO or wildtype animals. N=3; scale bar marks 5 µm. 
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 cGK-dependent phosphoprotein analysis  
Genomic deletion and knockdown of cGKII had a neuroprotective effect on for Cnga3 KO 
cones. This effect is most likely attributable to altered phosphorylation of cellular proteins due to 
the lack of cGKII. Therefore an experiment was designed to identify cGK-dependent 
phosphoproteins that are enriched in Cnga3 KO retina. Using titanium ion (Ti4+) chelated 
magnetic particles phosphorylated proteins were enriched out of full retina protein lysates wild 
type, Cnga3 KO, cGKI/A3 DKO, cGKII/A3 DKO mice and further analysed by label free 
quantification (LFQ) mass spectrometry (Fig 3.12 A).  
Proteins detected in the phospho-enriched lysates of Cnga3 KO mice but not in DKO lysates 
were classified as potential targets of the respective cGMP kinase. As visualized by the volcano 
plots in Figure 3.12 B-D, several proteins could be detected rather enriched in phospho-lysates of 
Cnga3 KO tissue compared to wildtype or cGKII/A3 DKO tissue. A plot visualizing the ratio 
between cGKI/Cnga3 DKO and cGKII/Cnga3 DKO further emphasizes that the kinases have 
different targets in the mouse retina. A potential protein not found in either wildtype or 
cGKII/Cnga3 KO but highly phosphorylated on two phosphorylation sites in Cnga3 KO and 
cGKI/Cnga3 DKO retina was ATM-Rad3-related protein (Atr) a serine/threonine-specific 
protein kinase (Figure 3.12 B-E). Atr belongs to the phosphatidylinositol 3-kinase-related kinase 
family and is known to be a sensor for DNA damage, activating DNA damage checkpoint and 
cell-cycle arrest by phosphorylating downstream effector proteins (Sancar et al., 2004). 
Atr is essential for replication (Brown and Baltimore, 2003, Murga et al., 2009) and therefore an 
important target in tumour biology. During double strand breaks (DSBs) the histone H2A 
histone family member X (H2AX) accumulates in close proximity to the DNA breakage site and 
gets phosphorylated by the phosphatidyl-inositol-3-kinase-related kinases family, including Atr. 
Accordingly the phosphorylated H2AX termed as γ-H2AX is a widely used marker for DNA 
damage and for the activity of Atr (Harper and Elledge, 2007). γ-H2AX is also found during 
apoptotic DNA-fragmentation (Rogakou et al., 2000) and senescing cells (Sedelnikova et al., 
2004). 
Atr seems to be mainly localized in Müller glia cells (Figure 3.13A). Atr can also be detected in 
the outer and inner segments of photoreceptors. Possible substrates of Atr that are carrying the 
recognition site are also mainly found in the outer segments of photoreceptors (Figure 3.13A). 
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The protein level of Atr in whole retina lysates of Cnga3 KO mice are unchanged in comparison 
to wildtype tissue (Figure3.13 B), but increase of Atr activity might be concluded from γ-H2AX 
staining, showing an accumulation of phosphorylated H2AX in cone nuclei of Cnga3 KO mice 
but not in those of Cnga3 ko/cGvKII DKO mice (Figure3.13 C). Furthermore H2AX-positive 
nuclei show a signal for Atr in the cell nucleus (Figure 3.12 C).  
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 Pathway analysis 
The pathophysiological events leading to cell death in cones of Achromatopsia patients are still 
not fully understood. Analysis of a microarray approach highlight the substantial transcriptional 
changes in the retina of Cnga3 KO mice during the degeneration process and might shed light 
into the unknown molecular mechanisms leading to cell death. Looking at the time point of four 
weeks after birth (PW4), more than double the amount of genes are misregulated compared to 
the genes detected eight weeks after birth (PW8). In total 561 genes were detected to have a 
changed expression pattern at PW4. Taking into account that cone cell death in Cnga3 KO mice 
has its peak at around PW4 (Arango-Gonzalez et al., 2014)), it is reasonable to assume that genes 
Cnga3 
model as confirmed by the pathway analysis. This analysis further predicted a disruption of genes 
migration of cone somata has been detected and described in Cnga3 KO mice (Michalakis et al., 
2005)
However the delay did not abolish the migration and cones in the adult Cnga3 KO retina show 
wildtype-like somata with a normal morphology and localization (Michalakis et al., 2005). 
lained 
by the high percentage of transcription factors with a changed expression pattern, detected by 
gene ontology analysis. Pathway analyses at PW8 rather display the consequences of gene 
-
substantial alteration in the cell morphology and might 
already imply a loss of photoreceptors.  
This microarray approach emphasizes that major gene expression alterations happen early in the 
degeneration process (PW4). Accordingly, to further understand cell death mechanisms in cones 
gene changes and pathway changes should be further examined at the time point of PW4. 
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 cGMP accumulation and cell death 
Accumulation of cGMP was shown in Cnga3 KO mice throughout the degeneration process. 
Remarkably, cGMP accumulation was already observed before eye opening and persisted as long 
as the cone cells survived.  
The detected cGMP-accumulation was cone specific and probably caused by a low calcium level 
(Figure4.1). Due to the loss of the CNG channel, calcium-influx is disrupted and the intracellular 
calcium level decreases. The guanylate cyclase activating protein (GCAP) is calcium-free and can, 
thus, directly bind and activate the membrane bound guanylate cyclase E (Gucy-E). Gucy-E gets 
activated upon binding and continuously produces cGMP regardless of a light stimulus. 
By knocking down Gucy-E, the only cGMP-producing enzyme in cones, a clear rescue of cone 
degeneration was detected. In the regions of shRNA expression in the retina, a higher percentage 
of cones survived compared to the uninjected control eye. This supports the hypothesis that the 
balance of the second messenger cGMP has a strong influence on the vitality of cones. A previous 
paper could already show that a knock-out of the guanylate cyclase has a protective effect on the 
survival of cones (Xu et al., 2013). The presented results of this study further support the 
previous published data and further shows that viral interference two weeks after birth is 
sufficient to prolong cone survival.  
GCAP 
Gucy 
GTP 
Ca²+ cGMP 
Figure 4.1:  cGMP accumulation in cones of Cnga3 ko 
mice. Loss of the cyclic nucleotide gated (CNG) cation channel 
leads to a decline of intracellular calcium levels. Thus Ca2+-free 
GCAP can activate the cGMP-producing guanylate cyclase 
(Gucy) and cGMP gets produced continuously. 
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Deficiency as well as sustained overload of the second messenger has both major consequences for 
the viability of photoreceptors. According to literature, knocking out the guanylyl cyclase and a 
loss of GCAPs leads to cone degeneration (Yang et al., 1999, Payne et al., 1998). Overload of 
cGMP in rods by knocking out the phosphodiesterase (PDE) as seen in the rd1 mouse leads to 
severe photoreceptor loss (McLaughlin et al., 1993, Drager and Hubel, 1978, Pittler and Baehr, 
1991).  
Surprisingly, high cGMP concentrations were detected at very early time points, long before eye 
opening and before the maturation of photoreceptors was fully accomplished. These results imply 
that Gucy-E, the CNG channel and the other visual cascade proteins are already active in cones 
around postnatal day four (P4). Most importantly these results show that cGMP accumulation 
has no influence on cone development and maturation. Apart from the delay of postnatal cone 
somata migration which has not been linked to cGMP so far, no deficits have been described in 
the cone development of Cnga3 KO mice (Michalakis et al., 2005).  
Contradictory to this early detection of cGMP, cell death is not detected in Cnga3 KO mice 
before week two and has its peak around 30 to 35 days after birth (Michalakis et al., 2005, 
Arango-Gonzalez et al., 2014). Since cGMP is detected from day four onwards, these results 
indicate that cGMP accumulation does not induce photoreceptor death before two weeks after 
birth. At this time point eye opening occurs. Thus cGMP-overload itself does not seem to be 
toxic for photoreceptors but as soon as light enters the eye and when the visual cascade is 
functional, cell death seems to set in. Looking closely at the targets regulated by cGMP, it is 
worth mentioning that in the Cnga3 KO retina cGKII shows an expression peak at P14 that 
matches the onset of degeneration. At this age cGKII is even significantly higher expressed in 
knockout mice compared to wildtype mice. The activation of the vision cascade by light might 
induce an up-regulation of cGKII due to an unknown cGMP-regulated transcription feed-back 
mechanism. The expression of cGKI on the other hand is relatively low at P6 and constantly rises 
until PW4 and shows no expression-difference between knockout and wildtype tissue. 
The progression of cell death in the Cnga3 KO mouse model is surprising compared to other 
mouse models. While most mouse models have a constantly ascending increase in the number of 
photoreceptors undergoing cell death, Cnga3 KO mice have a small number of TUNEL positive 
cells onward from the week two until 27 days after birth, when a sudden rise in cell death is 
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observed with a peak between 30-35 days after birth (Arango-Gonzalez et al., 2014). This 
indicates that a sudden mechanism sets in at about four weeks after birth. This hypothesis is 
further supported by the high number of genes detected in the microarray at the four week time 
point. An explanation would be that the high expression level of cGKII at P14 induces a 
downstream mechanism which first leads to cell death 2 weeks after induction. The expression 
level of cGKII drops back after the two week time point which would also explain the temporary 
peak of cell death.  
 
 Role of cGMP-dependent kinases in cone degeneration 
In this study, it was shown that high activity of the cGMP-kinase has vital consequences for 
photoreceptor survival. Conversely, photoreceptor-specific expression of the constitutively active 
cGK (CAcGK) induced a rapid degeneration and complete loss of the photoreceptor layer of 
wildtype mice. These results show that an enhanced activity of cGK induces cell death in 
photoreceptors. Nevertheless, the question remains which of the cGMP-dependent kinases might 
trigger the cell death signal. In a previous study the activity of cGK was measured in the retina of 
Nrl/Cnga3 DKO mice (Xu et al., 2013). Nrl KO mice are devoid of the neural retina leucine 
zipper (Nrl) and thus photoreceptor progenitor cells differentiate into S-cones instead of rods 
during development. This cone-dominant mouse model showed an enhanced activity of cGK. 
These findings are in line with the hypothesis that in the absence of CNGA3 increased cGMP 
levels trigger the activation of cGKs in affected cone photoreceptors.  
Evaluation of cone survival in cGKI/Cnga3 DKO or cGKII/Cnga3 DKO showed that lack of 
cGKII but not cGKI can distinctively delay cone cell death. Interestingly, genomic deletion of 
cGKI alone was not sufficient to rescue cone cell death and rather accelerated the degeneration 
process. This further emphasizes that cGKI and cGKII clearly have different targets and different 
functions in the retina. Surprisingly a triple knockout of cGKI, cGKII and Cnga3 led to a more 
pronounced rescue of cone degeneration. This might indicate that the downstream signalling of 
cGKI, e.g. in cones, might also trigger a cell death signal. cGKI/Cnga3 DKO mice might not 
show a rescue of cone cell death, due to the high expression of cGKI in Müller glia cells. The 
maintenance of Müller glia is essential for a healthy retina (Reichenbach and Bringmann, 2013, 
Bringmann et al., 2006). A global loss of cGKI expression might have major consequences for 
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Müller glia cells or might induce an immune response which might further promote cell death. 
Accordingly, a cone specific deletion or inhibition of cGKI is needed to clarify whether high 
activity of cGKI mediates cell death signalling in cones while it is indispensable for other cells like 
Müller glia. This would further explain why cGKII knockout is not sufficient to fully rescue the 
degeneration. Account should also be taken of a possible function of cGKII in other cell types of 
the retina or a role of cGKII during development. All these open questions emphasize the need 
for a cell-specific manipulation of these kinases.  
 
 Cell death signalling in photoreceptors 
The molecular mechanisms leading to cell death in retinal degenerations remain an open 
question. Several processes have been so far implicated in photoreceptor cell death (Pierce, 2001). 
Already a continuous activation of the visual transduction cascade leads to a degeneration of 
photoreceptors. High light exposure activates the transduction cascade and has been shown to 
lead to photoreceptor death in mice (Fain and Lisman, 1999). Furthermore, mutations in the 
alpha subunit of PDE or the guanylate cyclase are both causing a chronic activation of 
transduction and cause photoreceptor degeneration (Dryja et al., 1995, Perrault et al., 1996).  
Another important factor for photoreceptor survival are the retinal pigment epithelial (RPE) cells. 
It is well established that photoreceptor function and survival strongly depends on RPE cells 
(Marmorstein et al., 1998, Rizzolo, 1997, Bok, 1993) and that a dysfunction of the latter can 
lead to photoreceptor degeneration (Weng et al., 1999, Redmond et al., 1998). RPE cells are 
crucial for retinal homeostasis. They are not only important for nutrient supply to photoreceptors 
but also for recycling of the chromophore needed for phototransduction (Steinberg, 1985, Saari, 
2000).  
Disruptions in the photoreceptor outer segment morphogenesis have been identified to cause 
retinal cell death (Hagstrom et al., 1999, Molday, 1998, Hawkins et al., 1985). Unfortunately, 
the mechanisms are largely unknown but photoreceptors start to die secondary to a dysfunction 
observed in the morphogenesis of outer segments. 
A more recent hypothesis for retinal degeneration is the activation of calpain (Doonan et al., 
2003, Paquet-Durand et al., 2006, Donovan and Cotter, 2002, Azuma et al., 2004). High levels 
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of calcium have been detected in the rd1 mouse as a result of continuous activation of the CNG 
channel, by cGMP (Fox et al., 1999). At that time the calcium overload has been hypothesized to 
trigger apoptotic cell death in rods (Fox et al., 1999). Other studies gave indirect proof that high 
levels of calcium have toxic effects on photoreceptors, by applying calcium-blockers (Ozaki et al., 
2013, Bush et al., 2000). However, more recent studies could show that the high content of 
calcium triggers non-apoptotic pathways through calpain activation in the rd1 mouse (Doonan et 
al., 2003, Paquet-Durand et al., 2006) but also in light-induced retinal degeneration (Donovan 
and Cotter, 2002). 
A unique feature of photoreceptors is their ability to obtain energy from aerobic glycolysis 
(Winkler 1995). Photoreceptors drain vast amounts of energy to maintain their outer segments 
(Ames et al., 1992, Demontis et al., 1997). Thus they consume high amounts of oxygen, for their 
metabolism of glucose, and high amounts of glucose for glycolysis. Their oxygen consumption is 
three to four times higher compared to other retinal cells and to neuronal cells of the central 
nervous system (Alder et al., 1990, Braun et al., 1995). It has been shown that photoreceptors are 
vulnerable to inhibition of glycolysis and display a selective degeneration (Noell, 1951). They are 
further also susceptible to energy exhaustion and degenerate upon metabolic overload (Travis, 
1998, Tsang et al., 1996). 
Since the cGMP-directed pathway though cGKII activation does not completely rescue the 
phenotype, other mechanisms have to be taken into account as a possible explanation for cell 
death events in Achromatopsia. A continuous activation of the phototransduction cascade as well 
as a calcium-overload followed by calpain activation can be ruled out due to the lack of CNG 
channel in Cnga3 KO mice. RPE cells also seem to be unaffected in Achromatopsia patients and 
only start to degenerate in the fovea of humans at very late stages secondary to the observed cone 
loss (Thiadens et al., 2010b, Genead et al., 2011). However disruptions in the outer segments of 
Cnga3 KO mice have been described in the literature (Michalakis et al., 2005). The opsins seem 
to fail to be routed into the cone outer segments of Cnga3 KO mice. This impairment has already 
been suggested as a cause for cone loss (Michalakis et al., 2005). However, no mechanism has 
been found so far to further support this hypothesis. 
Another reasonable explanation is metabolic overload. Since cGMP metabolism is a main energy 
drain, a possible explanation for photoreceptor degeneration in Cnga3 KO mice could be energy 
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exhaustion by the intense production of cGMP. Only recently a study could proof that cone 
survival could be maintained by the stimulation of aerobic glycolysis (Ait-Ali et al., 2015). A 
factor called rod-derived cone viability factor (RdCVF), an inactive thioredoxin, is secreted by 
rods and binds in cones the transmembrane protein basigin-1 (BSG1) important for aerobic 
glycolysis. BSG1 directly binds the glutose transporter (GLUT1) and increases the entry of 
glucose which further stimulates aerobic glycolysis und leads to cone survival in rd1 mice (Ait-Ali 
et al., 2015). Since rods are unaffected by a Cnga3 mutation, RdCVF is not the limiting factor in 
Cnga3 KO mice but the study further supports the hypothesis that cones die upon a disruption of 
glycolysis. 
 
 cGKII signalling 
In order to gain a better understanding of the cGK dependent delay of photoreceptor death a 
phospho-specific mass-spectrometry approach was performed. With the phospho-proteom of the 
Cnga3 KO mouse line, potential substrates of cGKII were identified. The data reveal an 
important role for ataxia telangiectasia and Rad-3-related (Atr) in the Cnga3 KO mediated 
degeneration. Two specific Atr-phosphorylation-sites were enriched in Cnga3 KO and 
cGKI/Cnga3 DKO retina lysates compared to wildtype and cGKII/Cnga3 DKO retina lysates. 
These phosphorylation sites of Atr have not been reported before. Therefore no antibody was 
available specifically recognizing these phosphorylation-sites.  
Looking at the detected AA sequence, the consensus sequence (R/K(2-3)-X-S/T-X) of cGKII can 
be recognized at the enriched phosphorylation-site. Thus Atr might be a direct target of cGKII. 
Atr is a serine-threonine protein kinase and its activation is a hallmark of homologous 
recombination. Atr is activated upon double strand breaks (DSB) to initiate repair-mechanisms 
and cell survival (Cliby et al., 1998, Nghiem et al., 2001, Hurley and Bunz, 2007, Wilsker and 
Bunz, 2007, Nishida et al., 2009). Activation of Atr could be confirmed by γ-H2AX staining. 
Cnga3 KO nuclei showed several γ-H2AX-positive nuclei at PW4. The protein level of Atr is not 
changed in Cnga3 KO tissue indicating that the phosphorylation either influences the activation 
state or the localisation of the kinase. Immunohistochemical staining show that γ-H2AX-positive 
cones also show a signal for Atr in the cell nucleus. This indicates that Atr translocates into the 
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cell nucleus of Cnga3 KO cones. This translocation might be caused by cGKII-specific 
phosphorylation.  
Another proteomic approach on cone-nuclear extracts identified Npm1 as a highly enriched 
protein in cone-nuclei of Cnga3 KO mice. The role of NPM1 has been mainly investigated in 
proliferative cells but its function in post-mitotic neurons or retinal cells is largely unknown. An 
enrichment of Npm1 in cones compared to rods could be shown by immunohistochemistry. 
Immohistochemical stainings also indicated a higher level of Npm1 in the ONL of Cnga3 KO 
mice compared to wildtype mice. Both Atr and Npm1 are mainly localised nucleolar but can 
translocate to the nucleoplasm and cytoplasm. Interestingly, Npm1 is a target of Atr and can act 
towards cell survival and cell 
death (Pfister and D'Mello, 
2015). It can act pro-surival 
through PI3-K/Akt and 
MAPK/ERK signaling pathways 
(Ahn et al., 2005, Pfister and 
D'Mello, 2015). Furthermore, it 
can act protective against 
apoptotic events by either 
inhibiting p53 activation (Dhar 
and St Clair, 2009, Li et al., 
1998a) or by preventing caspase-
3-cleavage (Haindl et al., 2008, 
Liu et al., 2007). Nevertheless 
Npm1 can also act apoptotic 
through Bax protein, a co-factor 
of p53 (Dhar and St Clair, 2009, 
Geng et al., 2010, Li et al., 
1998a). Thus Npm1 seems to set 
a threshold of induction of cell 
death events. 
Figure 4.2:  Model for 
possible cGMP-signalling 
in Achromatopsia. By the 
accumulation of cGMP in 
cones cGMP-dependen 
kinase (cGK) II is activated 
and phosphorylates ataxia 
telangiectasia and Rad-3-
related (Atr). The 
phosphorylation enables Atr 
to translocate into the 
nucleus. In the nucleus it can 
than phosphorylate 
Nucleophosmin (Npm1) a 
protein mainly localized in 
the nucleus and an 
important player involved in 
survival and cell-death 
mechanisms. 
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Our hypothesis is that cGKII gets activated by the elevated cGMP level and phosphorylates the 
kinase Atr. Activated Atr in turn translocates into the nucleus of cones and phosphorylates Npm1 
and other targets. Npm1 might first activate cell survival mechanisms, but eventually triggers cell 
death due to a continuous activation  (Pfister and D'Mello, 2015). 
 
 Therapeutic applications 
The findings of this study unravel an important function of cGMP signalling in cone 
degeneration in the Cnga3 KO mouse model of Achromatopsia (Michalakis et al., 2013, Xu et 
al., 2013). The main focus of this study was to decrease the cell death signalling leading to cone 
loss in Achromatopsia; in particular, for enlarging the window of opportunity for gene-based 
therapies and for providing additional neuroptrotection in support of gene therapies. Treatment 
with cGKII shRNAs significantly slows down the degeneration mechanism. Thus the time 
window for treatment can be extended and cell death can be decreased during therapy. 
Further the data of this thesis might also help treating patients suffering from cone degeneration 
due to mutation not directly associated with the visual transduction cascade, e.g. in the recently 
discovered novel Achromatopsia gene ATF6 (Kohl 2015).  
A dysregulation of the cGMP production has already been identified as a trigger for rod 
degeneration and cell death in rd1 mice (Paquet-Durand et al., 2011, Paquet-Durand et al., 
2009). The rd1 mutation renders the PDE non-functional leading to cGMP overload due to the 
inability of the rod photoreceptor to cleave and metabolize this second messenger. However, due 
to elevated Ca2+ level, the current hypothesis for rod cell death in rd1 mice is activation of calpain 
(Paquet-Durand et al., 2011). However, in RP patients non-affected cones also degenerate 
secondary to rods. Thus in RP patients a cGK-inhibition might rescue the degeneration of cones 
which might be caused by an increase of cGMP and the effects of cGKII activation in cones since 
cGKII is hardly expressed in rods. 
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 Conclusion and Outlook 
It has previously been suggested that cGMP might contribute to the degeneration process in 
retinal degeneration (Farber and Lolley, 1974). More recent studies also suggested an important 
function of cGMP-signalling in cell death mechanisms of cones (Michalakis et al., 2013, Xu et 
al., 2013) but until today the importance of cGMP homeostasis in cone viability has not been 
understood. The data of this thesis helps clarifying this issue. It has been shown that the onset of 
cone degeneration is indeed influenced by cGMP and its downstream signalling. The proper 
control of the cellular levels of this crucial second messenger seems to be vital for the survival of 
cones (Figure3.2).  
The main effector of cGMP signalling leading to cell death in cone degeneration appears to be 
the cGMP-dependent kinase II. Loss of cGKII signalling by knockout or knockdown of the 
kinase could significantly delay cone photoreceptor degeneration in Cnga3 KO mice. Since 
therapeutic fine-tuning of cGMP-levels is rather difficult, cGKII might be a novel target for 
neuroprotection in cone degeneration. However, loss of cGKII was not able to fully rescue the 
cone cell death suggesting that additional mechanisms might contribute to cone degeneration. 
One explanation for this phenomenon could be that cGKI also triggers cell death through an 
unkown mechanism, and that both kinases must be targeted in a cell type-specific manner to fully 
rescue the degeneration process. cGMP-cGK signalling might have additional important 
functions in the retina and a global loss of the kinases might trigger a negative feedback. Thus a 
cell-specific knockout or knock-down would be advantageous. Other mechanisms possibly 
contributing to cell death are impaired opsin-targeting or metabolic overload caused by the 
intense cGMP production.  
Finally potential downstream targets of the cGKII were identified and cell death of cones might 
be triggered in Cnga3 KO mice by Npm1 through the serine/threonine kinase Atr. 
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 Summary 
Achromatopsia (ACHM) is a currently untreatable inherited eye disease that severely impairs 
daylight vision. The clinical manifestation results from cone photoreceptor dysfunction and is 
characterized by poor visual acuity, lack of colour discrimination and photophobia. In addition, a 
progressive degeneration and loss of macular cone photoreceptors is observed. In total six disease 
genes are known, but the majority of patients carries mutations in CNGA3 (29% of cases) or 
CNGB3 (48% of cases); the two genes encoding the cone cyclic nucleotide-gated (CNG) channel. 
This ion channel is directly gated by the second messenger cyclic GMP (cGMP) and is an integral 
part of the so called phototransduction cascade that translates light signals into electrical stimuli. 
Interestingly, genetic deletion of the CNG channel subunit CNGA3 in mice leads to high cellular 
levels of cGMP in affected cone photoreceptors. The aim of this thesis was to characterize the role 
of impaired cGMP signalling during cone photoreceptor degeneration in the Cnga3 knockout 
(KO) mouse model for ACHM. 
First, the developmental time course of cGMP accumulation was investigated using a cGMP-
specific antibody. One point worthy of note is that elevated cGMP levels could be observed as 
early as four days after birth. Using a virus-mediated in vivo gene knockdown (KD) approach it 
was possible to identify guanylate cyclase 2E (Gucy2e) as the main source of cGMP. Moreover, 
Gucy2e KD resulted in prolonged survival of cones in Cnga3 KO mice suggesting a toxic role of 
sustained cGMP overload in affected photoreceptors. Given the absence of CNG channels in 
Cnga3 KO cones this toxic effect has to be mediated by other cGMP targets. Promising 
candidates that were further investigated were the cGMP-dependent kinases (cGKs). To 
investigate the impact of elevated cGK signalling for photoreceptor viability a constitutively active 
cGK was overexpressed in wildtype mouse photoreceptors using viral vectors. This induced a 
dramatic decrease of the photoreceptor layer and demonstrated that these kinases can induce cell 
death. To verify this and to define the effect of the two kinase types, Cnga3 KO mice were cross-
bread with cGKI and cGKII KO mice and further examined morphologically. Global loss of 
cGKII but not cGKI significantly protected cone photoreceptors resulting in lower levels of 
degeneration and cell death. This finding was confirmed using viral vector-mediated delivery of a 
cGKII specific shRNA into cone photoreceptors of Cnga3 KO mice. Expression of cGKII-
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shRNA in adult Cnga3 KO mice again showed a decrease of degeneration suggesting cGKII as a 
novel target for neuroprotection in cone degeneration.  
Finally, to further unravel the cGMP signalling triggering cell death in cones two proteomic 
approaches were performed to identify potential downstream targets of cGKII. These screens 
could identify a link between a cGMP-cGK-signalling pathway and the serine/threonine kinase 
Atr. 
In conclusion this thesis presents strong evidence that cGMP-signalling accelerates retinal 
degeneration and identifies cGMP/cGKII signalling as a novel target for neuroprotective 
therapies to prolong cone survival in ACHM and other cone degenerations. 
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 Zusammenfassung 
Achromatopsie (ACHM) ist eine bis heute nicht heilbare erblich bedingte Augenkrankheit, die 
das Sehvermögen bei Tageslicht erheblich beeinträchtigt. Die Symptome entstehen durch eine 
Dysfunktion der Zapfen und sind geprägt von einem vollständigen Ausfall des Farbsinns, einer 
geringen Sehschärfe und einer extremen Blendungsempfindlichkeit der Betroffenen. Außerdem 
ist eine schnell fortschreitende Degeneration der Zapfen in der Makula zu beobachten. 
Mutationen in sechs Genen werden mit ACHM assoziiert, die meisten Patienten tragen jedoch 
eine Mutation in den Genen, die den in den Zapfen exprimierten zyklisch-Nukleotid gesteuerten 
(CNG) Kanal kodieren: CNGA3 (29 % der Fälle) und CNGB3 (48 % der Fälle). Dieser 
Ionenkanal wird durch Bindung des zellulären Botenstoffes - dem zyklischen GMP (cGMP) - 
geöffnet und ist zu
Phototransduktionskaskade), die Lichtsignale in elektrische Impulse umwandelt. 
Interessanterweise führt eine genetische Deletion der Untereinheit CNGA3 bei Mäusen zu einem 
erhöhten zellulären Level von cGMP in betroffenen Zapfen. Ziel dieser Arbeit war es, die Rolle 
der beeinträchtigten cGMP-Signalwege während der Zapfendegeneration des Cnga3 Knockout 
(KO) Mausmodelles zu charakterisieren. 
Zunächst wurde der entwicklungsspezifische Verlauf der cGMP Akkumulation untersucht. 
Überraschenderweise war bereits vier Tage nach der Geburt ein erhöhtes cGMP Level 
festzustellen. Mit Hilfe eines Virus-vermittelten Gen-Knockdowns (KD) war es möglich die 
Guanylatzyklase 2E (Gucy2E) als die Hauptquelle des cGMP in Zapfen zu identifizieren. 
Therapierte Augen zeigten eine erhöhte Zapfendichte, was darauf hinweist, dass eine cGMP-
Überlastung toxische Auswirkungen auf die betroffenen Zapfen hat. Ohne den CNG-Kanal in 
Cnga3 KO Zapfen kann die toxische Wirkung nur durch andere cGMP-Targets herbeigeführt 
werden. Vielversprechend für weitere Experimente erschienen dabei die cGMP-abhängigen 
Kinasen (cGKs), die weiter untersucht wurden. Um die Auswirkungen von erhöhten cGK-
Signalwegen zu untersuchen, wurde in Wildtypmäusen durch virale Vektoren eine konstitutiv 
aktive cGK überexprimiert. Dies hatte einen drastischen Verlust der Photorezeptorschicht zur 
Folge und zeigte, dass diese Kinasen Zelltod auslösen können. Um dies zu verifizieren wurden 
Cnga3 KO Mäuse mit cGKI und cGKII KO Mäusen gekreuzt und morphologisch untersucht. 
Ein globaler Verlust der cGKII nicht aber der cGKI schützte die Zapfen vor Zelltod und führte 
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zu einer signifikant verminderten Degeneration. Dieses Ergebnis wurde durch die Applikation 
einer cGKII-shRNA in Cnga3 KO Mäusen bestätigt, die ebenfalls einen signifikanten Rückgang 
des Zellsterbens zeigte. Diese Anwendung zeigt, dass cGKII ein möglicher neuer 
Anknüpfungspunkt für neuroprotektive Mechanismen in Zapfendegenerationen sein kann. 
Um letztendlich den cGMP Signalweg, der zum Zelltod führt, besser verstehen zu können, 
wurden mögliche Targets der cGKII durch zwei Massenspektrometrie-Ansätze identifiziert. Die 
Ergebnisse dieser Experimente weisen auf einen Zusammenhang zwischen dem cGMP-cGK-
Signalweg und der Serin/threonine Kinase Atr hin. 
Zusammenfassend liefert diese Arbeit aussagekräftige Nachweise, dass cGMP-Signalwege die 
retinale Degeneration beschleunigen und identifiziert einen cGMP-cGK Signalweg als neuen 
Anknüpfungspunkt für neuroprotektive Therapien um die Lebensdauer der Zapfen in ACHM 
und anderen Zapfendegenerationen zu verlängern. 
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SEQ  pAAV2.1-ss-Rho-cGKI-2A-GFP: 6692 bp; 
Vector from pAAV2.1-Rho-WPRE-MCS  4345bp AgeI+SacII 
Insert from pAAV2.1-ss-SWS-cGKI-GFP  2347bp; AgeI+SacII 
Insert position from 1306 
Composition  1620 A; 1776 C; 1701 G; 1595 T; 0 OTHER 
Percentage:  24.2%  A; 26.5%  C; 25.4%  G; 23.8%  T; 0.0%OTHER 
Molecular Weight (kDa): ssDNA: 2064.83 dsDNA: 4125.75 
KEYWORD     CIRCULAR 
 
ORIGIN 
1      AGCGCCCAAT ACGCAAACCG CCTCTCCCCG CGCGTTGGCC GATTCATTAA TGCAGCTGGC 
61     ACGACAGGTT TCCCGACTGG AAAGCGGGCA GTGAGCGCAA CGCAATTAAT GTGAGTTAGC 
121    TCACTCATTA GGCACCCCAG GCTTTACACT TTATGCTTCC GGCTCGTATG TTGTGTGGAA 
181    TTGTGAGCGG ATAACAATTT CACACAGGAA ACAGCTATGA CCATGATTAC GCCAGATTTA 
241    ATTAAGGCTG CGCGCTCGCT CGCTCACTGA GGCCGCCCGG GCAAAGCCCG GGCGTCGGGC 
301    GACCTTTGGT CGCCCGGCCT CAGTGAGCGA GCGAGCGCGC AGAGAGGGAG TGGCCAACTC 
361    CATCACTAGG GGTTCCTTGT AGTTAATGAT TAACCCGCCA TGCTACTTAT CTACGTAGCC 
421    ATGCTCTAGG AAGATCGGAA TTCGCCCTTA AGCTAGCAGA TCTTCCCCAC CTAGCCACCT 
481    GGCAAACTGC TCCTTCTCTC AAAGGCCCAA ACATGGCCTC CCAGACTGCA ACCCCCAGGC 
541    AGTCAGGCCC TGTCTCCACA ACCTCACAGC CACCCTGGAC GGAATCTGCT TCTTCCCACA 
601    TTTGAGTCCT CCTCAGCCCC TGAGCTCCTC TGGGCAGGGC TGTTTCTTTC CATCTTTGTA 
661    TTCCCAGGGG CCTGCAAATA AATGTTTAAT GAACGAACAA GAGAGTGAAT TCCAATTCCA 
721    TGCAACAAGG ATTGGGCTCC TGGGCCCTAG GCTATGTGTC TGGCACCAGA AACGGAAGCT 
781    GCAGGTTGCA GCCCCTGCCC TCATGGAGCT CCTCCTGTCA GAGGAGTGTG GGGACTGGAT 
841    GACTCCAGAG GTAACTTGTG GGGGAACGAA CAGGTAAGGG GCTGTGTGAC GAGATGAGAG 
901    ACTGGGAGAA TAAACCAGAA AGTCTCTAGC TGTCCAGAGG ACATAGCACA GAGGCCCATG 
961    GTCCCTATTT CAAACCCAGG CCACCAGACT GAGCTGGGAC CTTGGGACAG ACAAGTCATG 
1021   CAGAAGTTAG GGGACCTTCT CCTCCCTTTT CCTGGATGGA TCCTGAGTAC CTTCTCCTCC 
1081   CTGACCTCAG GCTTCCTCCT AGTGTCACCT TGGCCCCTCT TAGAAGCCAA TTAGGCCCTC 
1141   AGTTTCTGCA GCGGGGATTA ATATGATTAT GAACACCCCC AATCTCCCAG ATGCTGATTC 
1201   AGCCAGGAGC TTAGGAGGGG GAGGTCACTT TATAAGGGTC TGGGGGGGTC AGAACCCAGA 
1261   GTCATCCCCT GAATTCTGCA GATATCCATC ACACTGGCGG CCGCACCGGT CGACTAGAGG 
1321   ATCCACCATG GCATATGAAG ATGCAGAAGC TAAGGCAAAA TATGAAGCTG AAGCTGCTTT 
1381   CTTCGCCAAC CTGAAGCTGT CTGATTTCAA CATCATTGAC ACCCTTGGAG TTGGAGGTTT 
1441   CGGACGCGTA GAACTGGTCC AGTTAAAAAG TGAAGAATCC AAAACCTTTG CAATGAAGAT 
1501   TCTCAAGAAA CGCCACATCG TGGATACAAG ACAGCAGGAA CACATCCGCT CGGAGAAGCA 
1561   GATCATGCAG GGGGCCCATT CGGACTTCAT AGTGAGATTA TACAGAACAT TTAAGGACAG 
1621   CAAATATTTG TATATGTTGA TGGAAGCTTG CCTAGGTGGA GAGCTCTGGA CCATTCTCAG 
1681   GGATCGGGGG TCATTTGAAG ATTCTACAAC CAGATTTTAT ACAGCATGTG TGGTAGAAGC 
1741   TTTTGCCTAT CTGCATTCCA AAGGAATCAT TTACAGGGAC CTCAAGCCTG AAAATCTCAT 
1801   CCTAGATCAC CGAGGTTATG CCAAACTGGT TGATTTTGGC TTTGCAAAGA AAATAGGATT 
1861   TGGAAAGAAA ACATGGACTT TTTGTGGGAC TCCAGAATAT GTAGCCCCAG AGATCATCCT 
1921   GAACAAAGGC CATGACATTT CAGCCGACTA TTGGTCACTG GGAATCCTCA TGTATGAGCT 
1981   TCTGACTGGC AGCCCACCTT TCTCAGGCCC AGATCCTATG AAAACCTATA ACATCATATT 
2041   GAGGGGGATT GACATGATAG AGTTTCCAAA GAAGATTGCC AAAAATGCTG CTAATTTAAT 
2101   TAAAAAACTA TGCAGGGATA ATCCATCAGA AAGATTAGGG AATTTGAAAA ACGGAGTGAA 
2161   AGACATTCAA AAGCACAAAT GGTTTGAGGG CTTTAATTGG GAAGGCTTAA GAAAAGGCAC 
2221   CTTGACACCT CCTATAATAC CAAGTGTTGC ATCACCCACA GACACAAGCA ATTTTGACAG 
2281   TTTCCCTGAG GACAATGACG AACCGCCACC TGATGACAAC TCAGGATGGG ACATAGACTT 
2341   CGGTACCGGA GCCACGAACT TCTCTCTGTT AAAGCAAGCA GGAGACGTGG AAGAAAACCC 
2401   CGGTCCTACT AGTATGGTGA GCAAGGGCGA GGAGCTGTTC ACCGGGGTGG TGCCCATCCT 
2461   GGTCGAGCTG GACGGCGACG TAAACGGCCA CAAGTTCAGC GTGTCCGGCG AGGGCGAGGG 
2521   CGATGCCACC TACGGCAAGC TGACCCTGAA GTTCATCTGC ACCACCGGCA AGCTGCCCGT 
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2581   GCCCTGGCCC ACCCTCGTGA CCACCCTGAC CTACGGCGTG CAGTGCTTCA GCCGCTACCC 
2641   CGACCACATG AAGCAGCACG ACTTCTTCAA GTCCGCCATG CCCGAAGGCT ACGTCCAGGA 
2701   GCGCACCATC TTCTTCAAGG ACGACGGCAA CTACAAGACC CGCGCCGAGG TGAAGTTCGA 
2761   GGGCGACACC CTGGTGAACC GCATCGAGCT GAAGGGCATC GACTTCAAGG AGGACGGCAA 
2821   CATCCTGGGG CACAAGCTGG AGTACAACTA CAACAGCCAC AACGTCTATA TCATGGCCGA 
2881   CAAGCAGAAG AACGGCATCA AGGTGAACTT CAAGATCCGC CACAACATCG AGGACGGCAG 
2941   CGTGCAGCTC GCCGACCACT ACCAGCAGAA CACCCCCATC GGCGACGGCC CCGTGCTGCT 
3001   GCCCGACAAC CACTACCTGA GCACCCAGTC CGCCCTGAGC AAAGACCCCA ACGAGAAGCG 
3061   CGATCACATG GTCCTGCTGG AGTTCGTGAC CGCCGCCGGG ATCACTCTCG GCATGGACGA 
3121   GCTGTACAAG TAAAGCGGCC GCGTCGACAA TCAACCTCTG GATTACAAAA TTTGTGAAAG 
3181   ATTGACTGGT ATTCTTAACT ATGTTGCTCC TTTTACGCTA TGTGGATACG CTGCTTTAAT 
3241   GCCTTTGTAT CATGCTATTG CTTCCCGTAT GGCTTTCATT TTCTCCTCCT TGTATAAATC 
3301   CTGGTTGCTG TCTCTTTATG AGGAGTTGTG GCCCGTTGTC AGGCAACGTG GCGTGGTGTG 
3361   CACTGTGTTT GCTGACGCAA CCCCCACTGG TTGGGGCATT GCCACCACCT GTCAGCTCCT 
3421   TTCCGGGACT TTCGCTTTCC CCCTCCCTAT TGCCACGGCG GAACTCATCG CCGCCTGCCT 
3481   TGCCCGCTGC TGGACAGGGG CTCGGCTGTT GGGCACTGAC AATTCCGTGG TGTTGTCGGG 
3541   GAAGCTGACG TCCTTTCCAT GGCTGCTCGC CTGTGTTGCC ACCTGGATTC TGCGCGGGAC 
3601   GTCCTTCTGC TACGTCCCTT CGGCCCTCAA TCCAGCGGAC CTTCCTTCCC GCGGCCTGCT 
3661   GCCGGCTCTG CGGCCTCTTC CGCGTCTTCG AGATCTGCCT CGACTGTGCC TTCTAGTTGC 
3721   CAGCCATCTG TTGTTTGCCC CTCCCCCGTG CCTTCCTTGA CCCTGGAAGG TGCCACTCCC 
3781   ACTGTCCTTT CCTAATAAAA TGAGGAAATT GCATCGCATT GTCTGAGTAG GTGTCATTCT 
3841   ATTCTGGGGG GTGGGGTGGG GCAGGACAGC AAGGGGGAGG ATTGGGAAGA CAATAGCAGG 
3901   CATGCTGGGG ACTCGAGTTA AGGGCGAATT CCCGATTAGG ATCTTCCTAG AGCATGGCTA 
3961   CGTAGATAAG TAGCATGGCG GGTTAATCAT TAACTACAAG GAACCCCTAG TGATGGAGTT 
4021   GGCCACTCCC TCTCTGCGCG CTCGCTCGCT CACTGAGGCC GGGCGACCAA AGGTCGCCCG 
4081   ACGCCCGGGC TTTGCCCGGG CGGCCTCAGT GAGCGAGCGA GCGCGCAGCC TTAATTAACC 
4141   TAATTCACTG GCCGTCGTTT TACAACGTCG TGACTGGGAA AACCCTGGCG TTACCCAACT 
4201   TAATCGCCTT GCAGCACATC CCCCTTTCGC CAGCTGGCGT AATAGCGAAG AGGCCCGCAC 
4261   CGATCGCCCT TCCCAACAGT TGCGCAGCCT GAATGGCGAA TGGGACGCGC CCTGTAGCGG 
4321   CGCATTAAGC GCGGCGGGTG TGGTGGTTAC GCGCAGCGTG ACCGCTACAC TTGCCAGCGC 
4381   CCTAGCGCCC GCTCCTTTCG CTTTCTTCCC TTCCTTTCTC GCCACGTTCG CCGGCTTTCC 
4441   CCGTCAAGCT CTAAATCGGG GGCTCCCTTT AGGGTTCCGA TTTAGTGCTT TACGGCACCT 
4501   CGACCCCAAA AAACTTGATT AGGGTGATGG TTCACGTAGT GGGCCATCGC CCCGATAGAC 
4561   GGTTTTTCGC CCTTTGACGC TGGAGTTCAC GTTCCTCAAT AGTGGACTCT TGTTCCAAAC 
4621   TGGAACAACA CTCAACCCTA TCTCGGTCTA TTCTTTTGAT TTATAAGGGA TTTTTCCGAT 
4681   TTCGGCCTAT TGGTTAAAAA ATGAGCTGAT TTAACAAAAA TTTAACGCGA ATTTTAACAA 
4741   AATATTAACG TTTATAATTT CAGGTGGCAT CTTTCGGGGA AATGTGCGCG GAACCCCTAT 
4801   TTGTTTATTT TTCTAAATAC ATTCAAATAT GTATCCGCTC ATGAGACAAT AACCCTGATA 
4861   AATGCTTCAA TAATATTGAA AAAGGAAGAG TATGAGTATT CAACATTTCC GTGTCGCCCT 
4921   TATTCCCTTT TTTGCGGCAT TTTGCCTTCC TGTTTTTGCT CACCCAGAAA CGCTGGTGAA 
4981   AGTAAAAGAT GCTGAAGATC AGTTGGGTGC ACGAGTGGGT TACATCGAAC TGGATCTCAA 
5041   TAGTGGTAAG ATCCTTGAGA GTTTTCGCCC CGAAGAACGT TTTCCAATGA TGAGCACTTT 
5101   TAAAGTTCTG CTATGTGGCG CGGTATTATC CCGTATTGAC GCCGGGCAAG AGCAACTCGG 
5161   TCGCCGCATA CACTATTCTC AGAATGACTT GGTTGAGTAC TCACCAGTCA CAGAAAAGCA 
5221   TCTTACGGAT GGCATGACAG TAAGAGAATT ATGCAGTGCT GCCATAACCA TGAGTGATAA 
5281   CACTGCGGCC AACTTACTTC TGACAACGAT CGGAGGACCG AAGGAGCTAA CCGCTTTTTT 
5341   GCACAACATG GGGGATCATG TAACTCGCCT TGATCGTTGG GAACCGGAGC TGAATGAAGC 
5401   CATACCAAAC GACGAGCGTG ACACCACGAT GCCTGTAGTA ATGGTAACAA CGTTGCGCAA 
5461   ACTATTAACT GGCGAACTAC TTACTCTAGC TTCCCGGCAA CAATTAATAG ACTGGATGGA 
5521   GGCGGATAAA GTTGCAGGAC CACTTCTGCG CTCGGCCCTT CCGGCTGGCT GGTTTATTGC 
5581   TGATAAATCT GGAGCCGGTG AGCGTGGGTC TCGCGGTATC ATTGCAGCAC TGGGGCCAGA 
5641   TGGTAAGCCC TCCCGTATCG TAGTTATCTA CACGACGGGG AGTCAGGCAA CTATGGATGA 
5701   ACGAAATAGA CAGATCGCTG AGATAGGTGC CTCACTGATT AAGCATTGGT AACTGTCAGA 
5761   CCAAGTTTAC TCATATATAC TTTAGATTGA TTTAAAACTT CATTTTTAAT TTAAAAGGAT 
5821   CTAGGTGAAG ATCCTTTTTG ATAATCTCAT GACCAAAATC CCTTAACGTG AGTTTTCGTT 
5881   CCACTGAGCG TCAGACCCCG TAGAAAAGAT CAAAGGATCT TCTTGAGATC CTTTTTTTCT 
5941   GCGCGTAATC TGCTGCTTGC AAACAAAAAA ACCACCGCTA CCAGCGGTGG TTTGTTTGCC 
6001   GGATCAAGAG CTACCAACTC TTTTTCCGAA GGTAACTGGC TTCAGCAGAG CGCAGATACC 
6061   AAATACTGTC CTTCTAGTGT AGCCGTAGTT AGGCCACCAC TTCAAGAACT CTGTAGCACC 
6121   GCCTACATAC CTCGCTCTGC TAATCCTGTT ACCAGTGGCT GCTGCCAGTG GCGATAAGTC 
6181   GTGTCTTACC GGGTTGGACT CAAGACGATA GTTACCGGAT AAGGCGCAGC GGTCGGGCTG 
6241   AACGGGGGGT TCGTGCACAC AGCCCAGCTT GGAGCGAACG ACCTACACCG AACTGAGATA 
6301   CCTACAGCGT GAGCTATGAG AAAGCGCCAC GCTTCCCGAA GGGAGAAAGG CGGACAGGTA 
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6361   TCCGGTAAGC GGCAGGGTCG GAACAGGAGA GCGCACGAGG GAGCTTCCAG GGGGAAACGC 
6421   CTGGTATCTT TATAGTCCTG TCGGGTTTCG CCACCTCTGA CTTGAGCGTC GATTTTTGTG 
6481   ATGCTCGTCA GGGGGGCGGA GCCTATGGAA AAACGCCAGC AACGCGGCCT TTTTACGGTT 
6541   CCTGGCCTTT TGCTGCGGTT TTGCTCACAT GTTCTTTCCT GCGTTATCCC CTGATTCTGT 
6601   GGATAACCGT ATTACCGCCT TTGAGTGAGC TGATACCGCT CGCCGCAGCC GAACGACCGA 
6661   GCGCAGCGAG TCAGTGAGCG AGGAAGCGGA AG 
 
SEQ  pSub-U6-LoxP-sh Gucy-PGK-mcherry-WPRE: 6501 bp;Plasmid Construction: 
Composition  1575 A; 1700 C; 1715 G; 1511 T; 0 OTHER 
Percentage:  24.2%  A; 26.1%  C; 26.4%  G; 23.2%  T; 0.0%OTHER 
Molecular Weight (kDa): ssDNA: 2007.85 dsDNA: 4008.03 
KEYWORD     CIRCULAR 
 
ORIGIN 
1      CAGCTGCGCG CTCGCTCGCT CACTGAGGCC GCCCGGGCAA AGCCCGGGCG TCGGGCGACC 
61     TTTGGTCGCC CGGCCTCAGT GAGCGAGCGA GCGCGCAGAG AGGGAGTGGC CAACTCCATC 
121    ACTAGGGGTT CCTTGTAGTT AATGATTAAC CCGCCATGCT ACTTATCTAC GTAGCCATGC 
181    TCTAGGAAGA TCGGAATTCG CCCTTAAGCT AGCTTAATTA AATCCGACGC CGCCATCTCT 
241    AGGCCCGCGC CGGCCCCCTC GCACAGACTT GTGGGAGAAG CTCGGCTACT CCCCTGCCCC 
301    GGTTAATTTG CATATAATAT TTCCTAGTAA CTATAGAGGC TTAATGTGCG ATAAAAGACA 
361    GATAATCTGT TCTTTTTAAT ACTAGCTACA TTTTACATGA TAGGCTTGGA TTTCTATAAG 
421    AGATACAAAT ACTAAATTAT TATTTTAAAA AACAGCACAA AAGGAAACTC ACCCTAACTG 
481    TAAAGTAATT GTGTGTTTTG AGACTATAAA TATCCCTTGG AGAAAAGCCT TGTTATCGGT 
541    ACCATAACTT CGTATAGCAT ACATTATACG AAGTTATGAG CTCCGGTGCC CATGATGTCT 
601    ATAATCAAGA GTTATAGACA TCATGGGCAC CGTTTTTGAT ATCGAATTCC CACGGGGTTG 
661    GGGTTGCGCC TTTTCCAAGG CAGCCCTGGG TTTGCGCAGG GACGCGGCTG CTCTGGGCGT 
721    GGTTCCGGGA AACGCAGCGG CGCCGACCCT GGGTCTCGCA CATTCTTCAC GTCCGTTCGC 
781    AGCGTCACCC GGATCTTCGC CGCTACCCTT GTGGGCCCCC CGGCGACGCT TCCTGCTCCG 
841    CCCCTAAGTC GGGAAGGTTC CTTGCGGTTC GCGGCGTGCC GGACGTGACA AACGGAAGCC 
901    GCACGTCTCA CTAGTACCCT CGCAGACGGA CAGCGCCAGG GAGCAATGGC AGCGCGCCGA 
961    CCGCGATGGG CTGTGGCCAA TAGCGGCTGC TCAGCGGGGC GCGCCGAGAG CAGCGGCCGG 
1021   GAAGGGGCGG TGCGGGAGGC GGGGTGTGGG GCGGTAGTGT GGGCCCTGTT CCTGCCCGCG 
1081   CGGTGTTCCG CATTCTGCAA GCCTCCGGAG CGCACGTCGG CAGTCGGCTC CCTCGTTGAC 
1141   CGAATCACCG ACCTCTCTCC CCAGGGGGAT CCACCGGTAT GGTGAGCAAG GGCGAGGAGG 
1201   ATAACATGGC CATCATCAAG GAGTTCATGC GCTTCAAGGT GCACATGGAG GGCTCCGTGA 
1261   ACGGCCACGA GTTCGAGATC GAGGGCGAGG GCGAGGGCCG CCCCTACGAG GGCACCCAGA 
1321   CCGCCAAGCT GAAGGTGACC AAGGGTGGCC CCCTGCCCTT CGCCTGGGAC ATCCTGTCCC 
1381   CTCAGTTCAT GTACGGCTCC AAGGCCTACG TGAAGCACCC CGCCGACATC CCCGACTACT 
1441   TGAAGCTGTC CTTCCCCGAG GGCTTCAAGT GGGAGCGCGT GATGAACTTC GAGGACGGCG 
1501   GCGTGGTGAC CGTGACCCAG GACTCCTCCC TGCAGGACGG CGAGTTCATC TACAAGGTGA 
1561   AGCTGCGCGG CACCAACTTC CCCTCCGACG GCCCCGTAAT GCAGAAGAAG ACCATGGGCT 
1621   GGGAGGCCTC CTCCGAGCGG ATGTACCCCG AGGACGGCGC CCTGAAGGGC GAGATCAAGC 
1681   AGAGGCTGAA GCTGAAGGAC GGCGGCCACT ACGACGCTGA GGTCAAGACC ACCTACAAGG 
1741   CCAAGAAGCC CGTGCAGCTG CCCGGCGCCT ACAACGTCAA CATCAAGTTG GACATCACCT 
1801   CCCACAACGA GGACTACACC ATCGTGGAAC AGTACGAACG CGCCGAGGGC CGCCACTCCA 
1861   CCGGCGGCAT GGACGAGCTG TACAAGTAAG TTTAAACGTC GACAATCAAC CTCTGGATTA 
1921   CAAAATTTGT GAAAGATTGA CTGGTATTCT TAACTATGTT GCTCCTTTTA CGCTATGTGG 
1981   ATACGCTGCT TTAATGCCTT TGTATCATGC TATTGCTTCC CGTATGGCTT TCATTTTCTC 
2041   CTCCTTGTAT AAATCCTGGT TGCTGTCTCT TTATGAGGAG TTGTGGCCCG TTGTCAGGCA 
2101   ACGTGGCGTG GTGTGCACTG TGTTTGCTGA CGCAACCCCC ACTGGTTGGG GCATTGCCAC 
2161   CACCTGTCAG CTCCTTTCCG GGACTTTCGC TTTCCCCCTC CCTATTGCCA CGGCGGAACT 
2221   CATCGCCGCC TGCCTTGCCC GCTGCTGGAC AGGGGCTCGG CTGTTGGGCA CTGACAATTC 
2281   CGTGGTGTTG TCGGGGAAGC TGACGTCCTT TCCATGGCTG CTCGCCTGTG TTGCCACCTG 
2341   GATTCTGCGC GGGACGTCCT TCTGCTACGT CCCTTCGGCC CTCAATCCAG CGGACCTTCC 
2401   TTCCCGCGGC CTGCTGCCGG CTCTGCGGCC TCTTCCGCGT CTTCGAGATC TGCCTCGACT 
2461   GTGCCTTCTA GTTGCCAGCC ATCTGTTGTT TGCCCCTCCC CCGTGCCTTC CTTGACCCTG 
2521   GAAGGTGCCA CTCCCACTGT CCTTTCCTAA TAAAATGAGG AAATTGCATC GCATTGTCTG 
2581   AGTAGGTGTC ATTCTATTCT GGGGGGTGGG GTGGGGCAGG ACAGCAAGGG GGAGGATTGG 
2641   GAAGACAATA GCAGGCATGC TGGGGACTCG AGTTAAGGGC GAATTCCCGA TTAGGATCTT 
2701   CCTAGAGCAT GGCTACGTAG ATAAGTAGCA TGGCGGGTTA ATCATTAACT ACAAGGAACC 
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2761   CCTAGTGATG GAGTTGGCCA CTCCCTCTCT GCGCGCTCGC TCGCTCACTG AGGCCGGGCG 
2821   ACCAAAGGTC GCCCGACGCC CGGGCTTTGC CCGGGCGGCC TCAGTGAGCG AGCGAGCGCG 
2881   CAGCTGGGCC TCAGTGAGCG AGCGAGCGCG CAGCTGCATT AATGAATCGG CCAACGCGCG 
2941   GGGAGAGGCG GTTTGCGTAT TGGGCGCTCT TCCGCTTCCT CGCTCACTGA CTCGCTGCGC 
3001   TCGGTCGTTC GGCTGCGGCG AGCGGTATCA GCTCACTCAA AGGCGGTAAT ACGGTTATCC 
3061   ACAGAATCAG GGGATAACGC AGGAAAGAAC ATGTGAGCAA AAGGCCAGCA AAAGGCCAGG 
3121   AACCGTAAAA AGGCCGCGTT GCTGGCGTTT TTCCATAGGC TCCGCCCCCC TGACGAGCAT 
3181   CACAAAAATC GACGCTCAAG TCAGAGGTGG CGAAACCCGA CAGGACTATA AAGATACCAG 
3241   GCGTTTCCCC CTGGAAGCTC CCTCGTGCGC TCTCCTGTTC CGACCCTGCC GCTTACCGGA 
3301   TACCTGTCCG CCTTTCTCCC TTCGGGAAGC GTGGCGCTTT CTCATAGCTC ACGCTGTAGG 
3361   TATCTCAGTT CGGTGTAGGT CGTTCGCTCC AAGCTGGGCT GTGTGCACGA ACCCCCCGTT 
3421   CAGCCCGACC GCTGCGCCTT ATCCGGTAAC TATCGTCTTG AGTCCAACCC GGTAAGACAC 
3481   GACTTATCGC CACTGGCAGC AGCCACTGGT AACAGGATTA GCAGAGCGAG GTATGTAGGC 
3541   GGTGCTACAG AGTTCTTGAA GTGGTGGCCT AACTACGGCT ACACTAGAAG AACAGTATTT 
3601   GGTATCTGCG CTCTGCTGAA GCCAGTTACC TTCGGAAAAA GAGTTGGTAG CTCTTGATCC 
3661   GGCAAACAAA CCACCGCTGG TAGCGGTGGT TTTTTTGTTT GCAAGCAGCA GATTACGCGC 
3721   AGAAAAAAAG GATCTCAAGA AGATCCTTTG ATCTTTTCTA CGGGGTCTGA CGCTCAGTGG 
3781   AACGAAAACT CACGTTAAGG GATTTTGGTC ATGAGATTAT CAAAAAGGAT CTTCACCTAG 
3841   ATCCTTTTAA ATTAAAAATG AAGTTTTAAA TCAATCTAAA GTATATATGA GTAAACTTGG 
3901   TCTGACAGTT ACCAATGCTT AATCAGTGAG GCACCTATCT CAGCGATCTG TCTATTTCGT 
3961   TCATCCATAG TTGCCTGACT CCCCGTCGTG TAGATAACTA CGATACGGGA GGGCTTACCA 
4021   TCTGGCCCCA GTGCTGCAAT GATACCGCGA GACCCACGCT CACCGGCTCC AGATTTATCA 
4081   GCAATAAACC AGCCAGCCGG AAGGGCCGAG CGCAGAAGTG GTCCTGCAAC TTTATCCGCC 
4141   TCCATCCAGT CTATTAATTG TTGCCGGGAA GCTAGAGTAA GTAGTTCGCC AGTTAATAGT 
4201   TTGCGCAACG TTGTTGCCAT TGCTACAGGC ATCGTGGTGT CACGCTCGTC GTTTGGTATG 
4261   GCTTCATTCA GCTCCGGTTC CCAACGATCA AGGCGAGTTA CATGATCCCC CATGTTGTGC 
4321   AAAAAAGCGG TTAGCTCCTT CGGTCCTCCG ATCGTTGTCA GAAGTAAGTT GGCCGCAGTG 
4381   TTATCACTCA TGGTTATGGC AGCACTGCAT AATTCTCTTA CTGTCATGCC ATCCGTAAGA 
4441   TGCTTTTCTG TGACTGGTGA GTACTCAACC AAGTCATTCT GAGAATAGTG TATGCGGCGA 
4501   CCGAGTTGCT CTTGCCCGGC GTCAATACGG GATAATACCG CGCCACATAG CAGAACTTTA 
4561   AAAGTGCTCA TCATTGGAAA ACGTTCTTCG GGGCGAAAAC TCTCAAGGAT CTTACCGCTG 
4621   TTGAGATCCA GTTCGATGTA ACCCACTCGT GCACCCAACT GATCTTCAGC ATCTTTTACT 
4681   TTCACCAGCG TTTCTGGGTG AGCAAAAACA GGAAGGCAAA ATGCCGCAAA AAAGGGAATA 
4741   AGGGCGACAC GGAAATGTTG AATACTCATA CTCTTCCTTT TTCAATATTA TTGAAGCATT 
4801   TATCAGGGTT ATTGTCTCAT GAGCGGATAC ATATTTGAAT GTATTTAGAA AAATAAACAA 
4861   ATAGGGGTTC CGCGCACATT TCCCCGAAAA GTGCCACCTG ACGTCTAAGA AACCATTATT 
4921   ATCATGACAT TAACCTATAA AAATAGGCGT ATCACGAGGC CCTTTCGTCT CGCGCGTTTC 
4981   GGTGATGACG GTGAAAACCT CTGACACATG CAGCTCCCGG AGACGGTCAC AGCTTGTCTG 
5041   TAAGCGGATG CCGGGAGCAG ACAAGCCCGT CAGGGCGCGT CAGCGGGTGT TGGCGGGTGT 
5101   CGGGGCTGGC TTAACTATGC GGCATCAGAG CAGATTGTAC TGAGAGTGCA CCATATGCGG 
5161   TGTGAAATAC CGCACAGATG CGTAAGGAGA AAATACCGCA TCAGGCGATT CCAACATCCA 
5221   ATAAATCATA CAGGCAAGGC AAAGAATTAG CAAAATTAAG CAATAAAGCC TCAGAGCATA 
5281   AAGCTAAATC GGTTGTACCA AAAACATTAT GACCCTGTAA TACTTTTGCG GGAGAAGCCT 
5341   TTATTTCAAC GCAAGGATAA AAATTTTTAG AACCCTCATA TATTTTAAAT GCAATGCCTG 
5401   AGTAATGTGT AGGTAAAGAT TCAAACGGGT GAGAAAGGCC GGAGACAGTC AAATCACCAT 
5461   CAATATGATA TTCAACCGTT CTAGCTGATA AATTCATGCC GGAGAGGGTA GCTATTTTTG 
5521   AGAGGTCTCT ACAAAGGCTA TCAGGTCATT GCCTGAGAGT CTGGAGCAAA CAAGAGAATC 
5581   GATGAACGGT AATCGTAAAA CTAGCATGTC AATCATATGT ACCCCGGTTG ATAATCAGAA 
5641   AAGCCCCAAA AACAGGAAGA TTGTATAAGC AAATATTTAA ATTGTAAGCG TTAATATTTT 
5701   GTTAAAATTC GCGTTAAATT TTTGTTAAAT CAGCTCATTT TTTAACCAAT AGGCCGAAAT 
5761   CGGCAAAATC CCTTATAAAT CAAAAGAATA GACCGAGATA GGGTTGAGTG TTGTTCCAGT 
5821   TTGGAACAAG AGTCCACTAT TAAAGAACGT GGACTCCAAC GTCAAAGGGC GAAAAACCGT 
5881   CTATCAGGGC GATGGCCCAC TACGTGAACC ATCACCCTAA TCAAGTTTTT TGGGGTCGAG 
5941   GTGCCGTAAA GCACTAAATC GGAACCCTAA AGGGAGCCCC CGATTTAGAG CTTGACGGGG 
6001   AAAGCCGGCG AACGTGGCGA GAAAGGAAGG GAAGAAAGCG AAAGGAGCGG GCGCTAGGGC 
6061   GCTGGCAAGT GTAGCGGTCA CGCTGCGCGT AACCACCACA CCCGCCGCGC TTAATGCGCC 
6121   GCTACAGGGC GCGTACTATG GTTGCTTTGA CGAGCACGTA TAACGTGCTT TCCTCGTTAG 
6181   AATCAGAGCG GGAGCTAAAC AGGAGGCCGA TTAAAGGGAT TTTAGACAGG AACGGTACGC 
6241   CAGAATCCTG AGAAGTGTTT TTATAATCAG TGAGGCCACC GAGTAAAAGA GTCTGTCCAT 
6301   CACGCAAATT AACCGTTGTC GCAATACTTC TTTGATTAGT AATAACATCA CTTGCCTGAG 
6361   TAGAAGAACT CAAACTATCG GCCTTGCTGG TAATATCCAG AACAATATTA CCGCCAGCCA 
6421   TTGCAACGGA ATCGCCATTC GCCATTCAGG CTGCGCAACT GTTGGGAAGG GCGATCGGTG 
6481   CGGGCCTCTT CGCTATTACG C 
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SEQ  pSub-U6-LoxP-sh cGKII-PGK-mcherry-WPRE: 6501 bp; 
Composition  1576 A; 1699 C; 1714 G; 1512 T; 0 OTHER 
Percentage:  24.2%  A; 26.1%  C; 26.4%  G; 23.3%  T; 0.0%OTHER 
Molecular Weight (kDa): ssDNA: 2007.85 dsDNA: 4008.03 
ORIGIN 
1      CAGCTGCGCG CTCGCTCGCT CACTGAGGCC GCCCGGGCAA AGCCCGGGCG TCGGGCGACC 
61     TTTGGTCGCC CGGCCTCAGT GAGCGAGCGA GCGCGCAGAG AGGGAGTGGC CAACTCCATC 
121    ACTAGGGGTT CCTTGTAGTT AATGATTAAC CCGCCATGCT ACTTATCTAC GTAGCCATGC 
181    TCTAGGAAGA TCGGAATTCG CCCTTAAGCT AGCTTAATTA AATCCGACGC CGCCATCTCT 
241    AGGCCCGCGC CGGCCCCCTC GCACAGACTT GTGGGAGAAG CTCGGCTACT CCCCTGCCCC 
301    GGTTAATTTG CATATAATAT TTCCTAGTAA CTATAGAGGC TTAATGTGCG ATAAAAGACA 
361    GATAATCTGT TCTTTTTAAT ACTAGCTACA TTTTACATGA TAGGCTTGGA TTTCTATAAG 
421    AGATACAAAT ACTAAATTAT TATTTTAAAA AACAGCACAA AAGGAAACTC ACCCTAACTG 
481    TAAAGTAATT GTGTGTTTTG AGACTATAAA TATCCCTTGG AGAAAAGCCT TGTTATCGGT 
541    ACCATAACTT CGTATAGCAT ACATTATACG AAGTTATGAG CTCCGAACCT ATGACCTCAA 
601    CAAATCAAGA GTTTGTTGAG GTCATAGGTT CGTTTTTGAT ATCGAATTCC CACGGGGTTG 
661    GGGTTGCGCC TTTTCCAAGG CAGCCCTGGG TTTGCGCAGG GACGCGGCTG CTCTGGGCGT 
721    GGTTCCGGGA AACGCAGCGG CGCCGACCCT GGGTCTCGCA CATTCTTCAC GTCCGTTCGC 
781    AGCGTCACCC GGATCTTCGC CGCTACCCTT GTGGGCCCCC CGGCGACGCT TCCTGCTCCG 
841    CCCCTAAGTC GGGAAGGTTC CTTGCGGTTC GCGGCGTGCC GGACGTGACA AACGGAAGCC 
901    GCACGTCTCA CTAGTACCCT CGCAGACGGA CAGCGCCAGG GAGCAATGGC AGCGCGCCGA 
961    CCGCGATGGG CTGTGGCCAA TAGCGGCTGC TCAGCGGGGC GCGCCGAGAG CAGCGGCCGG 
1021   GAAGGGGCGG TGCGGGAGGC GGGGTGTGGG GCGGTAGTGT GGGCCCTGTT CCTGCCCGCG 
1081   CGGTGTTCCG CATTCTGCAA GCCTCCGGAG CGCACGTCGG CAGTCGGCTC CCTCGTTGAC 
1141   CGAATCACCG ACCTCTCTCC CCAGGGGGAT CCACCGGTAT GGTGAGCAAG GGCGAGGAGG 
1201   ATAACATGGC CATCATCAAG GAGTTCATGC GCTTCAAGGT GCACATGGAG GGCTCCGTGA 
1261   ACGGCCACGA GTTCGAGATC GAGGGCGAGG GCGAGGGCCG CCCCTACGAG GGCACCCAGA 
1321   CCGCCAAGCT GAAGGTGACC AAGGGTGGCC CCCTGCCCTT CGCCTGGGAC ATCCTGTCCC 
1381   CTCAGTTCAT GTACGGCTCC AAGGCCTACG TGAAGCACCC CGCCGACATC CCCGACTACT 
1441   TGAAGCTGTC CTTCCCCGAG GGCTTCAAGT GGGAGCGCGT GATGAACTTC GAGGACGGCG 
1501   GCGTGGTGAC CGTGACCCAG GACTCCTCCC TGCAGGACGG CGAGTTCATC TACAAGGTGA 
1561   AGCTGCGCGG CACCAACTTC CCCTCCGACG GCCCCGTAAT GCAGAAGAAG ACCATGGGCT 
1621   GGGAGGCCTC CTCCGAGCGG ATGTACCCCG AGGACGGCGC CCTGAAGGGC GAGATCAAGC 
1681   AGAGGCTGAA GCTGAAGGAC GGCGGCCACT ACGACGCTGA GGTCAAGACC ACCTACAAGG 
1741   CCAAGAAGCC CGTGCAGCTG CCCGGCGCCT ACAACGTCAA CATCAAGTTG GACATCACCT 
1801   CCCACAACGA GGACTACACC ATCGTGGAAC AGTACGAACG CGCCGAGGGC CGCCACTCCA 
1861   CCGGCGGCAT GGACGAGCTG TACAAGTAAG TTTAAACGTC GACAATCAAC CTCTGGATTA 
1921   CAAAATTTGT GAAAGATTGA CTGGTATTCT TAACTATGTT GCTCCTTTTA CGCTATGTGG 
1981   ATACGCTGCT TTAATGCCTT TGTATCATGC TATTGCTTCC CGTATGGCTT TCATTTTCTC 
2041   CTCCTTGTAT AAATCCTGGT TGCTGTCTCT TTATGAGGAG TTGTGGCCCG TTGTCAGGCA 
2101   ACGTGGCGTG GTGTGCACTG TGTTTGCTGA CGCAACCCCC ACTGGTTGGG GCATTGCCAC 
2161   CACCTGTCAG CTCCTTTCCG GGACTTTCGC TTTCCCCCTC CCTATTGCCA CGGCGGAACT 
2221   CATCGCCGCC TGCCTTGCCC GCTGCTGGAC AGGGGCTCGG CTGTTGGGCA CTGACAATTC 
2281   CGTGGTGTTG TCGGGGAAGC TGACGTCCTT TCCATGGCTG CTCGCCTGTG TTGCCACCTG 
2341   GATTCTGCGC GGGACGTCCT TCTGCTACGT CCCTTCGGCC CTCAATCCAG CGGACCTTCC 
2401   TTCCCGCGGC CTGCTGCCGG CTCTGCGGCC TCTTCCGCGT CTTCGAGATC TGCCTCGACT 
2461   GTGCCTTCTA GTTGCCAGCC ATCTGTTGTT TGCCCCTCCC CCGTGCCTTC CTTGACCCTG 
2521   GAAGGTGCCA CTCCCACTGT CCTTTCCTAA TAAAATGAGG AAATTGCATC GCATTGTCTG 
2581   AGTAGGTGTC ATTCTATTCT GGGGGGTGGG GTGGGGCAGG ACAGCAAGGG GGAGGATTGG 
2641   GAAGACAATA GCAGGCATGC TGGGGACTCG AGTTAAGGGC GAATTCCCGA TTAGGATCTT 
2701   CCTAGAGCAT GGCTACGTAG ATAAGTAGCA TGGCGGGTTA ATCATTAACT ACAAGGAACC 
2761   CCTAGTGATG GAGTTGGCCA CTCCCTCTCT GCGCGCTCGC TCGCTCACTG AGGCCGGGCG 
2821   ACCAAAGGTC GCCCGACGCC CGGGCTTTGC CCGGGCGGCC TCAGTGAGCG AGCGAGCGCG 
2881   CAGCTGGGCC TCAGTGAGCG AGCGAGCGCG CAGCTGCATT AATGAATCGG CCAACGCGCG 
2941   GGGAGAGGCG GTTTGCGTAT TGGGCGCTCT TCCGCTTCCT CGCTCACTGA CTCGCTGCGC 
3001   TCGGTCGTTC GGCTGCGGCG AGCGGTATCA GCTCACTCAA AGGCGGTAAT ACGGTTATCC 
3061   ACAGAATCAG GGGATAACGC AGGAAAGAAC ATGTGAGCAA AAGGCCAGCA AAAGGCCAGG 
3121   AACCGTAAAA AGGCCGCGTT GCTGGCGTTT TTCCATAGGC TCCGCCCCCC TGACGAGCAT 
3181   CACAAAAATC GACGCTCAAG TCAGAGGTGG CGAAACCCGA CAGGACTATA AAGATACCAG 
3241   GCGTTTCCCC CTGGAAGCTC CCTCGTGCGC TCTCCTGTTC CGACCCTGCC GCTTACCGGA 
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3301   TACCTGTCCG CCTTTCTCCC TTCGGGAAGC GTGGCGCTTT CTCATAGCTC ACGCTGTAGG 
3361   TATCTCAGTT CGGTGTAGGT CGTTCGCTCC AAGCTGGGCT GTGTGCACGA ACCCCCCGTT 
3421   CAGCCCGACC GCTGCGCCTT ATCCGGTAAC TATCGTCTTG AGTCCAACCC GGTAAGACAC 
3481   GACTTATCGC CACTGGCAGC AGCCACTGGT AACAGGATTA GCAGAGCGAG GTATGTAGGC 
3541   GGTGCTACAG AGTTCTTGAA GTGGTGGCCT AACTACGGCT ACACTAGAAG AACAGTATTT 
3601   GGTATCTGCG CTCTGCTGAA GCCAGTTACC TTCGGAAAAA GAGTTGGTAG CTCTTGATCC 
3661   GGCAAACAAA CCACCGCTGG TAGCGGTGGT TTTTTTGTTT GCAAGCAGCA GATTACGCGC 
3721   AGAAAAAAAG GATCTCAAGA AGATCCTTTG ATCTTTTCTA CGGGGTCTGA CGCTCAGTGG 
3781   AACGAAAACT CACGTTAAGG GATTTTGGTC ATGAGATTAT CAAAAAGGAT CTTCACCTAG 
3841   ATCCTTTTAA ATTAAAAATG AAGTTTTAAA TCAATCTAAA GTATATATGA GTAAACTTGG 
3901   TCTGACAGTT ACCAATGCTT AATCAGTGAG GCACCTATCT CAGCGATCTG TCTATTTCGT 
3961   TCATCCATAG TTGCCTGACT CCCCGTCGTG TAGATAACTA CGATACGGGA GGGCTTACCA 
4021   TCTGGCCCCA GTGCTGCAAT GATACCGCGA GACCCACGCT CACCGGCTCC AGATTTATCA 
4081   GCAATAAACC AGCCAGCCGG AAGGGCCGAG CGCAGAAGTG GTCCTGCAAC TTTATCCGCC 
4141   TCCATCCAGT CTATTAATTG TTGCCGGGAA GCTAGAGTAA GTAGTTCGCC AGTTAATAGT 
4201   TTGCGCAACG TTGTTGCCAT TGCTACAGGC ATCGTGGTGT CACGCTCGTC GTTTGGTATG 
4261   GCTTCATTCA GCTCCGGTTC CCAACGATCA AGGCGAGTTA CATGATCCCC CATGTTGTGC 
4321   AAAAAAGCGG TTAGCTCCTT CGGTCCTCCG ATCGTTGTCA GAAGTAAGTT GGCCGCAGTG 
4381   TTATCACTCA TGGTTATGGC AGCACTGCAT AATTCTCTTA CTGTCATGCC ATCCGTAAGA 
4441   TGCTTTTCTG TGACTGGTGA GTACTCAACC AAGTCATTCT GAGAATAGTG TATGCGGCGA 
4501   CCGAGTTGCT CTTGCCCGGC GTCAATACGG GATAATACCG CGCCACATAG CAGAACTTTA 
4561   AAAGTGCTCA TCATTGGAAA ACGTTCTTCG GGGCGAAAAC TCTCAAGGAT CTTACCGCTG 
4621   TTGAGATCCA GTTCGATGTA ACCCACTCGT GCACCCAACT GATCTTCAGC ATCTTTTACT 
4681   TTCACCAGCG TTTCTGGGTG AGCAAAAACA GGAAGGCAAA ATGCCGCAAA AAAGGGAATA 
4741   AGGGCGACAC GGAAATGTTG AATACTCATA CTCTTCCTTT TTCAATATTA TTGAAGCATT 
4801   TATCAGGGTT ATTGTCTCAT GAGCGGATAC ATATTTGAAT GTATTTAGAA AAATAAACAA 
4861   ATAGGGGTTC CGCGCACATT TCCCCGAAAA GTGCCACCTG ACGTCTAAGA AACCATTATT 
4921   ATCATGACAT TAACCTATAA AAATAGGCGT ATCACGAGGC CCTTTCGTCT CGCGCGTTTC 
4981   GGTGATGACG GTGAAAACCT CTGACACATG CAGCTCCCGG AGACGGTCAC AGCTTGTCTG 
5041   TAAGCGGATG CCGGGAGCAG ACAAGCCCGT CAGGGCGCGT CAGCGGGTGT TGGCGGGTGT 
5101   CGGGGCTGGC TTAACTATGC GGCATCAGAG CAGATTGTAC TGAGAGTGCA CCATATGCGG 
5161   TGTGAAATAC CGCACAGATG CGTAAGGAGA AAATACCGCA TCAGGCGATT CCAACATCCA 
5221   ATAAATCATA CAGGCAAGGC AAAGAATTAG CAAAATTAAG CAATAAAGCC TCAGAGCATA 
5281   AAGCTAAATC GGTTGTACCA AAAACATTAT GACCCTGTAA TACTTTTGCG GGAGAAGCCT 
5341   TTATTTCAAC GCAAGGATAA AAATTTTTAG AACCCTCATA TATTTTAAAT GCAATGCCTG 
5401   AGTAATGTGT AGGTAAAGAT TCAAACGGGT GAGAAAGGCC GGAGACAGTC AAATCACCAT 
5461   CAATATGATA TTCAACCGTT CTAGCTGATA AATTCATGCC GGAGAGGGTA GCTATTTTTG 
5521   AGAGGTCTCT ACAAAGGCTA TCAGGTCATT GCCTGAGAGT CTGGAGCAAA CAAGAGAATC 
5581   GATGAACGGT AATCGTAAAA CTAGCATGTC AATCATATGT ACCCCGGTTG ATAATCAGAA 
5641   AAGCCCCAAA AACAGGAAGA TTGTATAAGC AAATATTTAA ATTGTAAGCG TTAATATTTT 
5701   GTTAAAATTC GCGTTAAATT TTTGTTAAAT CAGCTCATTT TTTAACCAAT AGGCCGAAAT 
5761   CGGCAAAATC CCTTATAAAT CAAAAGAATA GACCGAGATA GGGTTGAGTG TTGTTCCAGT 
5821   TTGGAACAAG AGTCCACTAT TAAAGAACGT GGACTCCAAC GTCAAAGGGC GAAAAACCGT 
5881   CTATCAGGGC GATGGCCCAC TACGTGAACC ATCACCCTAA TCAAGTTTTT TGGGGTCGAG 
5941   GTGCCGTAAA GCACTAAATC GGAACCCTAA AGGGAGCCCC CGATTTAGAG CTTGACGGGG 
6001   AAAGCCGGCG AACGTGGCGA GAAAGGAAGG GAAGAAAGCG AAAGGAGCGG GCGCTAGGGC 
6061   GCTGGCAAGT GTAGCGGTCA CGCTGCGCGT AACCACCACA CCCGCCGCGC TTAATGCGCC 
6121   GCTACAGGGC GCGTACTATG GTTGCTTTGA CGAGCACGTA TAACGTGCTT TCCTCGTTAG 
6181   AATCAGAGCG GGAGCTAAAC AGGAGGCCGA TTAAAGGGAT TTTAGACAGG AACGGTACGC 
6241   CAGAATCCTG AGAAGTGTTT TTATAATCAG TGAGGCCACC GAGTAAAAGA GTCTGTCCAT 
6301   CACGCAAATT AACCGTTGTC GCAATACTTC TTTGATTAGT AATAACATCA CTTGCCTGAG 
6361   TAGAAGAACT CAAACTATCG GCCTTGCTGG TAATATCCAG AACAATATTA CCGCCAGCCA 
6421   TTGCAACGGA ATCGCCATTC GCCATTCAGG CTGCGCAACT GTTGGGAAGG GCGATCGGTG 
6481   CGGGCCTCTT CGCTATTACG C 
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